Pathogenesis of Systemic Sclerosis by Debendra Pattanaik et al.
June 2015 | Volume 6 | Article 2721
Review
published: 08 June 2015
doi: 10.3389/fimmu.2015.00272
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Giuseppe Alvise Ramirez, 
Università Vita-Salute San Raffaele, 
Italy
Reviewed by: 
F. David Carmona, 
Instituto de Parasitología y 
Biomedicina ‘Lopez-Neyra’ (CSIC), 
Spain 
Enrico Tombetti, 
San Raffaele Scientific Institute, Italy
*Correspondence:
 Arnold E. Postlethwaite, 
Department of Medicine, Division of 
Connective Tissue Diseases, The 
University of Tennessee Health 
Science Center, 956 Court Avenue, 
Room G326, Memphis, 
TN 38163-0001, USA 
 apostlet@uthsc.edu
Specialty section: 
This article was submitted to 
Inflammation, a section of the journal 
Frontiers in Immunology
Received: 19 November 2014
Accepted: 16 May 2015
Published: 08 June 2015
Citation: 
Pattanaik D, Brown M, 
Postlethwaite BC and 
Postlethwaite AE (2015) 
Pathogenesis of systemic sclerosis. 
Front. Immunol. 6:272. 
doi: 10.3389/fimmu.2015.00272
Pathogenesis of systemic sclerosis
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Systemic scleroderma (SSc) is one of the most complex systemic autoimmune diseases.
It targets the vasculature, connective tissue-producing cells (namely fibroblasts/myofi-
broblasts), and components of the innate and adaptive immune systems. Clinical and
pathologic manifestations of SSc are the result of: (1) innate/adaptive immune system
abnormalities leading to production of autoantibodies and cell-mediated autoimmunity, (2) 
microvascular endothelial cell/small vessel fibroproliferative vasculopathy, and (3) fibroblast
dysfunction generating excessive accumulation of collagen and other matrix components 
in skin and internal organs. All three of these processes interact and affect each other. The 
disease is heterogeneous in its clinical presentation that likely reflects different genetic or
triggering factor (i.e., infection or environmental toxin) influences on the immune system,
vasculature, and connective tissue cells. The roles played by other ubiquitous molecular
entities (such as lysophospholipids, endocannabinoids, and their diverse receptors and
vitamin D) in influencing the immune system, vasculature, and connective tissue cells are
just beginning to be realized and studied and may provide insights into new therapeutic
approaches to treat SSc.
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introduction
Systemic sclerosis (SSc, scleroderma) is a complex connective tissue disease of unknown etiology 
with multiorgan involvement and heterogeneous clinical manifestations. The clinical and pathologic 
manifestations of the disease are the result of three distinct processes: (1) innate and adaptive immune 
system abnormalities leading to production of autoantibodies and cell-mediated autoimmunity, (2) 
microvascular endothelial cells (MVEC) and fibroproliferative vasculopathy of small vessels, and (3) 
fibroblast dysfunction leading to excessive collagen (CI) and other matrix components accumulation 
in skin, blood vessels, and internal organs (1, 2).
The incidence of SSc is about 20 cases per million populations per year and the prevalence is more 
than 250 patients per million populations in USA (3). Major organ involvement leads to decreased 
survival in SSc. Pulmonary fibrosis [interstitial lung disease (ILD)] and pulmonary arterial hyperten-
sion (PAH) cause more than half of all SSc-related deaths (3). However, patients with SSc live longer 
and cardiac deaths are increasing.
Progressive thickening and fibrosis of skin secondary to excessive CI accumulation is the most 
evident and universal finding and can be associated with varying degrees of fibrosis of internal 
organs. Vascular dysfunction and abnormalities are often seen, and can precede organ involvement 
by several years (4).
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Abbreviations: 2-AG, 2-arachidonoyl glycerol; α2AP, α2-antiplasmin; AA, 
African American; ACA, anticentromere antibodies; Acea, eicosatetrae-
namide; ACR, American College of Rheumatology; ADCC, antibody-
dependent cellular cytotoxicity; AEA, anandamide; AFA, anti-fibrillarin 
antibody; AIF1, allograft inflammatory factor-1; AKT, protein kinase b; 
ALAS2, delta-aminolevulinate synthase 2 protein; ALK, activin receptor-
like kinase; ANA, antinuclear antibodies; APC, antigen-presenting cells; 
ARA, anti-U3 ribonucleoprotein; αSMA, α smooth muscle cell actin; ATA, 
anti-DNA topoisomerase I antibody; ATGL, adipose triglyceride lipase; 
aTregs, activated Tregs; αZAP, α zinc-finger alpha protein gene; BANK1, 
B-cell scaffold protein with ankyrin repeats 1; bFGF, basic fibroblasts 
growth factor; BiP, immunoglobulin-heavy-chain binding protein; BLM, 
bleomycin; BMP, bone morphogenic protein; BP, binding protein; Bregs, 
B regulatory cells; Cav-1, caveolin-1; CB1/CB2, cannabinoid receptors 
1 and CB2 ditto; CBP, CREB-binding protein; CCR1, C–C chemokine 
receptor type 1 protein or gene; CD40L, CD40 ligand; CGRP, calcitonin 
G-related peptide; CGS, candidate gene study; cGVHD, chronic graft-
versus-host disease; CI, type I collagen; CII, type II collagen; CIII, type 
III collagen; COX-2, cyclooxygenase 2 (i.e., prostaglandin synthase 2); 
CpG, C phosphate G; cScl-GVHD, chronic scleroderma graft-versus-host 
disease; CSK, C-src tyrosine kinase; CTGF, connective tissue growth fac-
tor; CV, type V collagen; CXCL4, angiostatin, platelet factor-4; DAMPs, 
damage-associated molecular patterns; dcSSc, diffuse cutaneous systemic 
scleroderma; DNAM-1, DNAX accessory molecule-1 (i.e., CD226); ECM, 
extracellular matrix; EC(s), endocannabinoid(s); ECS, endocannabinoid 
system; EDNR-A or -B, gene that encodes endothelin receptor type A or 
B; Egr-1, early response gene 1; eNOS, endothelial nitric oxide synthase; 
ERK, extracellular signal-regulated kinase; ET-1, endothelin-1; EVI, even-
ness interrupted, in reference to cell surface multipass transmembrane 
protein; FAAH, fatty acid amide hydrolase; FasL, Fas ligand; FGF, fibro-
blast growth factor; FH-1, human fetal lung fibroblast line; Fli(1), friend 
leukemia integration; Fra-2, Fos-related antigen-2; FTY720, fingolimod; 
GATA-3, GATA binding protein-3; GMCSF, granulocyte monocyte-
colony stimulating factor; GPCRs, G-protein-coupled receptors; GVHD, 
graft-versus-host disease; GWAS, genome-wide association studies; 
hCMV, human cytomegalovirus; HGF, hepatocyte growth factor; HLA, 
human leukocyte antigen; HMGB-1, high-mobility group box-1 protein; 
HMW-MAA, high molecular weight melanoma-associated antigen; HSP, 
heat-shock protein; IC, intracellular; ICAM-1, intercellular adhesion 
molecule-1; IFIT1, IFIT2, and IFITM1, interferon-regulated genes; IFN, 
interferon; IFNRI, type 1 interferon receptor; IGF, insulin-like growth fac-
tor; IGF-BP-5, insulin-like growth factor binding protein-5; ILCs, innate 
lymphoid cells; ILD, interstitial lung disease; IP, interferon-inducible pro-
tein; IPAH, idiopathic PAH; IPF, idiopathic pulmonary fibrosis; IRAK1, 
interleukin-1 receptor associated kinase 1; IRF, interferon regulatory 
factors; IRFSNP, interferon regulator factor, SNP (see entry); ITGAM, 
integrin αM; ITGAX, integrin αX; JAMs, junctional adhesion molecules; 
JNK, c-Jun N-terminal kinase; KCNA5, potassium voltage-gated channel, 
shaker-related subfamily, member 5 gene; kDA, kilo Dalton, measurement 
of; LAP, latency-associated peptides; lcSSc, limited cutaneous systemic 
scleroderma; LLC, large latent complex; LPA, lysophosphatidic acid; 
LPS, lipopolysaccharides; LTBP, latent TGF-β1-binding protein; MAGL, 
Disease manifestations vary from limited skin involvement 
with minimal systemic involvement [limited cutaneous (lc) SSc] 
to widespread skin involvement accompanied by internal organ 
involvement [diffuse cutaneous (dc) SSc]. These two forms differ 
mainly in regards to extent of skin involvement, autoantibody 
association, and the pattern of organ involvement (Table 1) (5). 
Given the heterogeneity of clinical symptoms and signs, American 
College of Rheumatology (ACR)/EULAR recently developed new 
classification criteria (6). The new classification criteria would 
improve sensitivity, which would lead to earlier diagnosis, and it 
also incorporates the autoantibodies that are commonly used for 
diagnostic purposes.
It is widely believed that SSc develops in an individual with 
a “permissive” genetic makeup. Genetic associations of SSc are 
monoacylglycerol lipase; MAPK, mitogen-activated protein kinase; MCP-
3, monocyte chemoattractant protein-3; MCR1, melanocortin receptor 
1, gene found in yeast; MECP2, methyl-CpG-binding protein 2 gene; 
MHC, major histocompatibility complex; MIF, macrophage migration 
inhibitory factor; MIP, macrophage inflammatory protein; miRNA, micro 
RNA (miR); MMP, matrix metalloproteinase; mPGES-1, microsomal 
prostaglandin E2 synthase 1; mRNA, messenger RNA; MRSS, modified 
Rodnan skin score; MS, multiple sclerosis; MVEC, microvascular endothe-
lial cells; MW, molecular weight; NAG-2, MVEC surface protein tetraspan 
novel antigen-2; NLR, a pattern recognition system (NOD)-like receptor 
family; NO, nitric oxide; NOD, nucleotide-binding and oligomerization 
domain; NOTCH, neurogenic locus notch homolog 4 protein encoded by 
the NOTCH4 gene, and an evolutionarily conserved pathway in multicel-
lular organisms that regulates cell-fate determination during development 
and maintains adult tissue homeostasis; NSIP, non-specific interstitial 
pneumonia; PAI, plasminogen activator inhibitor; PAH, pulmonary 
arterial hypertension; PAMPs, pathogen-associated molecular patterns; 
PAR, protease-activated receptor; PASMC, pulmonary artery smooth 
muscle cells; PBMC, peripheral blood mononuclear cell; PDGF/PDGFR, 
platelet-derived growth factor/receptor; PECAM, platelet/endothelial 
cell adhesion molecule; PG, prostaglandin; PGF, placental growth factor; 
PG-Gs, microsomal prostaglandins; PI-3, phosphatidylinositol 3; PLD4, 
phospholipase D family member 4; PPARγ, peroxisome proliferation-
activated receptor gamma; PRR, a pattern recognition receptor system 
in cell cytoplasm; PSD3, pleckstrin and Sec7 domain containing 3 gene; 
PTEN, phosphatase and tensin homolog; PTPN22, protein tyrosine 
phosphatase non-receptor type 22; PXK, paraxylene–orthoxylene (phox 
homology) domain containing serine/threonine kinase; RA, rheumatoid 
arthritis; RANTES, regulated upon activation, normal T-cell expressed and 
secreted; RGS-5, regulator of G protein signaling 5; RLRs, RIG-I-like recep-
tors; RORγt, RAR-related orphan nuclear receptor gamma transcription 
factor; RP, Raynaud’s phenomenon; R-Smads, receptor-regulated Smads; 
rTregs, resting Tregs; S1P/S1P1, sphingosine 1-phosphate (type 1 receptor); 
scl GVHD, sclerodermatoses GVHD; Serpine 1, plasminogen activator 
inhibitor; Siglec-1, CD169, sialoadhesin; siRNA, small interfering RNA; 
SLE, systemic lupus erythematosus; Smad, small mother against decapen-
taplegic family of transcription factors; Snail-1, a protein of the C2H2-type 
zinc-finger family that regulates transcription; SNPs, single nucleotide 
polymorphisms; sRAGE, soluble advanced glycation end products; SSc, 
systemic scleroderma; STAT, signal transducer and activator of transcrip-
tion; TG, transgenic; TGF-β, transforming growth factor beta; TIMP-1 or 
-2, tissue inhibition of metalloproteinase-1 or -2; TLRs, toll-like receptors; 
TNFAIP3, tumor necrosis factor alpha-induced protein-3; TNFSF4, tumor 
necrosis factor superfamily member 4 gene; TNIP1, TNFAIP3 interact-
ing protein-1; tPA, tissue t plasminogen activator; Tregs, T regulatory 
cells; TRPV, transient receptor potential vanilloid; Tsk-1 (Tsk-1/+), tight 
skin; TSP-1 or TSP-2, thrombospondin-1 or -2; UPAR, urokinase-type 
plasminogen activator receptor; VDR, vitamin D receptor; VE, vascular 
endothelial; VEGF, vascular endothelial growth factor; VitD, Vitamin D; 
VW, von Willebrand Factor; Wnt, proteins that form a family of highly 
conserved secreted signaling molecules that regulate cell-to-cell interac-
tions during embryogenesis; WT, wild-type.
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summarized below. A triggering event such as an infection or 
environmental toxin has been implicated as starting the processes 
that lead eventually to SSc in individuals with a permissive genetic 
background. The realization that an “interferon (IFN) signature” 
exists in most patients with SSc implies activation of the innate 
immune system and lends validity to the long-held suspicion that 
infections (such as with cytomegalovirus, Epstein-Barr virus, and 
more recently Toxoplasma gondii) could be SSc triggers in receiving 
more attention and a re-examination (7, 8). There is mounting 
evidence that the microbiota may play a role in development of 
autoimmunity, an area that is unexplored in SSc (9). Analysis 
of skin transcriptome has identified high levels of Rhodotorula 
sequences in dcSSc patients (10).
No animal model develops SSc that faithfully replicates human 
SSc, and this has impeded our understanding of the disease. There 
are many unresolved questions related to the etiopathogenesis of 
SSc. For example, it is unclear whether the innate/adaptive immune 
system abnormalities, vasculopathy, and fibroblast dysfunctions 
are separate, unrelated processes or are mechanistically linked, 
which of the three processes is of utmost importance and how 
interaction among the three processes leads to the development 
of the disease. These three processes will be discussed.
We first review evidence for genetic abnormalities in SSc since 
they can influence responses of the innate and adaptive immune 
systems, vascular function, connective tissue metabolism, and 
fibroblast function. Since the innate and adaptive immune 
systems are the first to respond to environmental triggers, be 
they infections or toxins in nature, and through generations of 
cytokines, chemokines, and growth factors that can affect function 
of vascular and connective tissue cells, we discuss them next. The 
vascular abnormalities and fibrosis in SSc are then discussed. The 
endocannabinoid system (ECS) (which influences functions of the 
immune system, vasculature, and fibroblasts) may be dysregulated 
in SSc as suggested by recent studies of SSc dermal fibroblasts. We 
have included a discussion of this important system with special 
emphasis on potential ECS targets that might offer new therapeutic 
approaches for management of SSc. Lysophospholipids [lysophos-
phatidic acid (LPA) and sphingosine 1-phosphate (S1P)] and their 
different receptors (which regulate immunity, vascular physiology, 
and fibrosis) are dysregulated in SSc and likely contribute to the 
pathogenesis of the disease. Vitamin D (VitD) status also impacts 
function of most cell types and likely influences pathogenesis and 
TABLe 1 | important differences between limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).
Features lcSSc dcSSc
Skin Skin thickening occurs late, limited to the distal part of 
upper and lower extremities, face, neck, and upper chest. 
Telangiectasias and calcinosis are common. Tendon friction rub 
not seen
Skin thickening occurs early, moves up to proximal part of 
extremities and trunk. Telangiectasias and calcinosis may occur 
late in disease. Tendon friction rub present
GI Esophageal dysmotility is more common than small and large 
intestine involvement
Esophageal dysmotility is frequently seen. Small and large 
intestinal involvement is more common
Pulmonary Pulmonary fibrosis is less frequent and less severe. Frequent 
and severe pulmonary hypertension is more common
Pulmonary fibrosis is more common and severe. Pulmonary 
hypertension is less frequent
Kidney Renal crisis uncommon Renal crisis is more frequent
Autoantibody association Anticentromere antibodies (ACA) are predominant Anti-DNA topoisomerase I antibody (ATA) (Anti-Scl-70) antibody 
is predominant
Anti-RNA polymerase antibody is more common
clinical features of SSc. An overall scheme of SSc pathogenesis is 
illustrated in Figure 1.
Genetics of SSC
Genetic influences have long been suspected to impact SSc. In 
families with a history of SSc, the incidence of disease can range 
from 1.5 to 1.7% (11). Having a family history of SSc increases the 
risk of developing disease 15–19-fold in siblings and 13–15-fold 
in first-degree relatives (11–13). Over the last decade, candidate 
gene study (CGS) approach and genome-wide association 
studies (GWAS) have been used to identify genetic associations 
that confer susceptibility to SSc. CGS and GWAS have allowed 
for the identification of genetic variations [single nucleotide 
polymorphisms (SNPs)] that are likely to be involved with the 
pathogenesis of scleroderma. CGS analyses SNPs to determine if 
the gene has association with a disease or a disease trait. The SNPs 
being studied have been selected based on their known association 
with other autoimmune diseases or on their possible functional 
relevance in the disease pathogenesis. GWAS arrays on the other 
hand, use tagSNPs to scan the entire genome to identify millions 
of SNPs. It takes into consideration the haplotype structure of 
the population being studied. Unlike CGS, GWAS identifies 
SNPs in a non-hypotheses-driven manner and allows for the 
identification of newly identifiable genes that were not previously 
identified in the disease. As regards to SSc, GWAS has confirmed 
major histocompatibility complex (MHC) II region as being most 
significant in this disease. Both CGS and GWAS have identified 
multiple genes that have been found to have firm associations in 
the pathogenesis of SSc.
Performing a GWAS can be very costly. Recently, the immuno-
chip consortium was developed and implemented the immuno-
chip analysis assay. The immunochip array provides high-density 
mapping of autoimmune diseases-associated loci using a custom 
SNP genotyping array (14). It was designed to increase efficiency 
of mapping autoimmunity risk loci and to reduce the cost of map-
ping (15). The immunochip uses variants from across 186 known 
autoimmunity risk loci and places them on an Illumina Infinium 
array platform. The platform contains 196,524 different variants of 
autoimmunity risk loci that may have functional significant effects 
in diseases like SSc. It also identifies variants with lower penetrance 
using a cost efficient strategy (14). Many of these genes have been 
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firmly established in the pathogenesis of SSc. In this review, we 
will focus on genetic associations in MHC – human leukocyte 
antigen (HLA, Table  2), non-HLA genetic SNP (Table  3), and 
microRNAs (miRNAs) (Table  4). We will focus on the most 
relevant associations first and then discuss others that may have 
modest effects on SSc.
HLA Association with SSc
The HLA-1 complexes HLA-A, -B, -C, and -G and HLA class-II 
complexes HLA-DP, -DQ, and -DR have all been identified in 
SSc susceptibility (11, 17, 108, 109) (Table 2). HLA class-II is the 
most significant region associated with SSc (14). HLA-DRB1*01, 
HLA-DRB1*11, HLA-A*30, and HLA-A*32 have SSc susceptibility, 
while HLA-DRB1*07, HLA-B*57, and HLA-Cw*14 are protective 
against SSc (17). HLA alleles DRB1*0802 and DQA1*0501 are 
associated with increased mortality (110). Clinical features of 
disease, disease phenotype, and SSc-specific autoantibodies have 
been distinguished based on HLA subtypes (Table 1). In a GWAS 
study that included 5471 SSc patients of European ancestry, HLA-
DQB1 locus was associated with anticentromere antibodies (ACA), 
HLA-DPA1/B1 loci with anti-DNA topoisomerase I antibody 
(ATA), and neurogenic locus notch homolog 4 (NOTCH4) with 
ACA and ATA (24). In another study that included SSc patients 
of African American (AA) and Hispanic descent, DRB1*1104, 
DQA1*0501, DQB1*0301, and DQB1 had strong positive associa-
tion in SSc patients of Hispanic and of European ancestry (24, 31). 
DRB1*0404, DRB1*11, and DQB1*03 alleles are associated with 
anti-U3 ribonucleoprotein (ARA) in this subpopulation (24). In 
this same subpopulation, DRB1*0701, DQA1*0201, DQB1*0202, 
and DRB1*1501 had a negative or protective association against SSc 
(27). These studies have also identified DRB1*11 with association 
FiGURe 1 | A simplified schematic of SSc pathogenesis, illustrating 
influences of a permissive genetic background and 
lysophospholipids and endocannabinoid system participation which 
have the capacity, if dysregulated, to effect changes in  
vasculature, fibroblasts, and innate and adaptive immune systems. 
See text for details.
with ATA and DRB1*01, DRB1*04, and DRB1*0501 have associa-
tion with ACA (31). HLA-DPB1 and HLA-DPB2 SNPs rs7763822/
rs7764491 and rs3117230/rs3128965 have strong association with 
ATA or ACA positivity (25). In AA patients with SSc, DRB1*0804, 
DQA1*0501, and DQB1*0301 are associated with SSc (28), and 
have a higher frequency of ARA or anti-fibrillarin antibody (AFA) 
positivity (111).
HLA-DRB1*1101, *1104, *1501, and *0802 (commonly 
associated with the dcSSc subset) show the amino acid sequence 
67FLEDR71 in their β chain, whereas HLA-D Q β1 alleles *D301, 
*0302, *0401, *0402, *0601, and *0602 (commonly associated with 
SSc) show a 71TRAELDT77 motif on their β chain (29). In a study in 
French SSc patients with European ancestry, both FLEDR and, to a 
lesser degree, TRAELDT were associated with dcSSc (29). Addition 
of a tyrosine at position 30 strengthened the TRAELDT association 
with dcSSc (29). Further analysis showed that the FLEDR motif 
had the highest association with SSc patients who were ATA posi-
tive, while TRAELDT had lesser association in this subset (29). 
The TRAELDT association with ATA positivity and dcSSc were 
not dependent entirely on FLEDR (29). The authors concluded 
that double dose of the shared epitope, as well as compound 
heterozygosity, may confer a higher risk for development of SSc.
HLA-DPB1 and -DPB2 are reported to have strong suscep-
tibility with SSc in the Korean and Chinese populations (25). 
Subtypes DPB1*1301 and DPB1*0901 were most common in 
Korean patients with SSc, while DPB1*03:01, DPB1*13:01, 
DQB1*03:03, DQB1*05:01, and DQB1*06:11 were significantly 
increased in the Chinese SSc patient population (26). Those 
who carried the DPB1*03:01 had a higher chance of develop-
ing pulmonary fibrosis verses those who carried DPB1*04, and 
those SSc patients were more likely to be ACA positive (112). 
DQB1*03:03 and DQB1*05:01 were strongly associated with 
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TABLe 2 | HLA genes associated with SSc.
HLA-associated genes Population (n = SSc) Disease phenotype  
and/or clinical features
Autoantibody association Reference
HLA CLASS i GeNeS ASSOCiATeD wiTH SSc
A*30 Brazil (141) Pulmonary fibrosis ATA (16, 17), (16, 18–22), (17), (17), 
(16), (18), (17), (23)B*13 European ancestry (95) PAH
B*35 Brazil PAH
Native Indian dcSSc
Hispanic
B*62 European ancestry (95) dcSSc and high skin scores, 
pulmonary fibrosis
B*65 PAH
C*04 Brazil PAH
Cw4 Native Indian Pulmonary fibrosis dcSSc pulmonary fibrosis ATA
Cw*0602 European ancestry (95) Pulmonary fibrosis ARA
G European ancestry Lower vascular cutaneous 
ulcers telangiectasias 
arthropathy
dcSSc
African
Brazilian
HLA CLASS-ii GeNeS ASSOCiATeD wiTH SSc
DPA1/B1 European ancestry (5,471) Pulmonary fibrosis ATA (24–26)
DPB1*1301 Korean Chinese (338) ACA, ATA, and dcSSc
*0901 ATA
DPB1/B2 SNPs
rs3128930
rs7763822/rs7764491 European ancestry (1,107) ACA
rs3117230/rs3128965
rs3117230 Caucasian
rs7763822 African American ACA
rs7764491 Hispanic ATA
rs3117230
rs312965
rs3128965A
DPA1/B1
DQA1 African American Pulmonary fibrosis ATA/ACA (16, 18, 19, 26–30)
*0501 Native American dcSSc
DQB1 ACA
*03:01 European ancestry Anti-U1RNP/
*03:03 Korean/Chinese ATA
*04:00 Hispanic
*05:01 Italian
*06:11 Brazilian ATA
*26:00 Native American
71TRAELDT77 French (282) dcSSc ATA
DRB1 European ancestry (17–19, 29–34)
Hispanic
Italian
*01 ACA
*0404 ACA
*05 ACA
*07
*0804 African American (278) AFA/ARA
*11 Increased skin score, 
pulmonary fibrosis
ATA
*1104 ACA
ATA
*1502 Thai (50) No association PF, DU, 
sclerodactyly, myositis, SICCA
ATA
*1602 Native American (32) dcSSc PF ATA
*0407 European ancestry Renal crisis dcSSc
African American
Hispanic (1,517)
*1304 European ancestry
African American
Hispanic (1,517)
DRB5*01:02 Thai (50) ATA
67FLEDR71 French (282) dcSSc ATA
(Continued)
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HLA-associated genes Population (n = SSc) Disease phenotype  
and/or clinical features
Autoantibody association Reference
NOTCH4 European ancestry (5,471) ACA (24)
ATA
GeNeS wiTH NeGATive ASSOCiATiON FOR SSc
C*03 Brazilian PAH ATAq (16, 27, 30, 33)
Spanish
DQA1 European ancestry (1,300)
*0201 Hispanic
*0501 Italian Spanish (940) dcSSc
DQB1 European ancestry
*0202 Hispanic
*04 Brazilian dcSSc
DRB1 Brazilian
*01 Spanish
*04 Thai
*0701
*1501
TABLe 2 | Continued
TABLe 3 | Non-HLA genes associated with SSc listed from largest to smallest SSc population analyzed.
No. Non-HLA-
associated 
genes
Other diseases 
identified
Study type Population 
(n = SSc)
Polymorphism/SNPs 
(OR)
Disease 
association
Proposed  
function
Reference
1 BANK1 SLE Case–control 
meta-analysis 
cohort
European 
ancestry 
(21,568)
rs10516487*G (1.12), 
rs17266594*T (1.14), 
rs3733197* A (0.73), AA 
(0.41), AG (0.85)
dcSSc ATA+ Mobilization of 
calcium from 
intracellular stores in 
B-cell receptor
(35–37)
2 IRF5 SLE, RA, UC GWAS 
meta-analysis 
immunochip array 
case–control 
cohorts
European and 
Asian ancestry 
(15,251)
rs2004640 (0.84), 
rs2004640*TT (1.56), 
rs10488631 (1.63), 
rs4728142 (1.22)
dcSSc, lcSSc, 
ATA, ACA, 
interstitial lung, 
longer survival 
mild PF
Regulate IFN-gene 
expression and 
inflammatory cytokine 
production. Stimulate 
TLR expression
(38–42), 
(42–44), (14, 
45, 46)
3 PXK SLE Immunochip pan-
meta-analysis 
GWAS
European 
ancestry 
(12,685)
rs2176082 (1.21), 
rs4681851 (1.58)
SSc, ACA Degradation 
and trafficking of 
epidermal growth 
factor
(14, 47)
4 STAT4 SLE, RA, 
primary biliary 
cirrhosis
GWAS 
immunochip 
meta-analysis 
cohort, case–
control cohorts
Multi-ethnic 
ancestry 
(10,696)
rs7574865 (1.29), 
additive effect with IRF5 
rs2004640 (1.72-2.752), 
rs11889341 (1.33), 
rs7574865*, TT vs. 
GG (0.49), TT vs. TG 
(0.48), TT + TG vs. GG 
(0.74), T vs. G (0.72), 
rs10168266*, CC (0.69), 
T (1.44)
lcSSc, ACA, 
fibrosing 
alveolitis, 
increased in 
patients who 
carry TBX21 
CC genotype, 
dcSSc, ATA, 
pulmonary 
fibrosis
T-cell signaling 
and differentiation; 
signaling IFN1; 
regulate cytokine 
signals
(38, 48–54)
5 PTPN22 DM-1, RA, SLE Meta-analysis 
case–control 
cohorts
Multi-ethnic 
and European 
ancestry 
(10,204)
PTPN22 CT/TT (2.21) 
higher risk of SSc than 
PTPN22 CC (1.70), 
PTPN22, C1858T 
[rs2476601* T (1.15)], 
[1858 T (1.147)], 1858 C
ATA and ACA, 
ACA, protective
T-cell receptor 
signaling
(55–58)
6 TNFSF4 SLE Meta-analysis 
cohort
European 
ancestry 
(10,093)
rs1234314 (1.15), 
rs12039904 (1.18), 
rs2205960*AA (1.33), 
rs844648 (1.10), 
rs844644 (0.91)
dcSSc, lcSSc and 
ACA+, protective 
in all sub-groups 
of SSc except 
ARA+
B-cell proliferation 
and differentiation 
T-cell stimulation and 
survival
(48, 59–61)
7 BLK SLE Case–control 
meta-analysis
European and 
Asian ancestry 
(9,305)
rs2736340 (1.27), 
rs13277113 (1.16), 
C8orf13-BLK, and 
BANK1 additive effect, 
FAM167-BLK
dcSSc, dcSSc, 
dcSSc, lcSSc
Disruption in B-cell 
gene expression 
and abnormal NFκB 
signaling
(48, 62–64)
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TABLe 3 | Continued
No. Non-HLA-
associated 
genes
Other diseases 
identified
Study type Population 
(n = SSc)
Polymorphism/SNPs 
(OR)
Disease 
association
Proposed  
function
Reference
8 IL-2, IL-2RA SSc Case–control 
cohort
European 
(7,516)
IL-2: rs6822844 (0.86), 
rs907715 (0.91), 
rs2069762*A- (1.06), 
rs6822844*T- (0.86), 
rs683545*G (0.93), 
rs907715*T (0.91); 
IL-2RA genes: 
rs11594656, rs2104286 
(1.30), rs12722495
SSc, lcSSc, 
dcSSc, and 
lcSSc when 
ACA+
T-cell proliferation 
and turning off T-cell 
response
(65, 66)
9 DNASE1L3 SLE, RA Immunochip European 
ancestry (7,169)
rs35677470 (2.03) ACA Defective apoptotic 
DNA breakdown
(14, 46)
10 JAZF1 SLE GWAS 
pan-meta-analysis
European 
ancestry (6,835)
rs1635852 (1.13) SSc Repress transcription (47)
11 KIAA0319L SLE, dyslexia GWAS 
pan-meta-analysis
European 
ancestry (6,835)
rs2275247 (1.49) lcSSc Protein coding (47)
12 IL-12Rβ2 Psoriasis, 
Behcet’s 
disease, primary 
biliary cirrhosis
GWAS European 
ancestry (6,250)
rs3790567 (1.17), 
rs2305743* A/G (0.81), 
rs8109496* C/G (0.82), 
rs436857* A/G (0.81), 
rs11668601* C/T (0.84)
SSc Stimulates IFN 
production and TH1 
differentiation
(67)
13 IRF8 SLE Cohort 
meta-analysis
European and 
Asian ancestry 
(6,201)
rs11642873 (0.75), 
rs2280381 (1.36)
lcSSc Regulate IFN-gene 
expression and 
inflammatory 
cytokine production. 
Stimulate TLR 
expression
(24, 68)
14 CD247 SLE GWAS European 
ancestry (6,080)
rs2056626 (0.78) SSc-G minor 
allele protective 
effect
T-cell signaling and 
activation
(49, 69)
15 ATG5 SLE Immunochip European 
ancestry (5,850)
Intron rs9373839* G 
(1.19)
SSc Autophagy vesicle 
formation
(14)
16 IL-12A-SCHIP Primary biliary 
cirrhosis, 
idiopathic 
pulmonary 
fibrosis
Immunochip European 
ancestry (5,850)
rs77583790 (2.81), 
intergenic between 
SCHIP1 and IL-12A
LcSSc Stimulates IFN 
production and TH1 
differentiation
(14)
17 CSK SLE, RA GWAS European 
ancestry (5,270)
rs1378942 (1.2) SSc Cell regulation, 
differentiation, 
migration, and 
immune response
(70)
18 PSD3 Hepato-cellular 
carcinoma
GWAS European 
ancestry (5,270)
rs10096702 (1.18) SSc Binding protein for 
signal transduction
(66)
19 IL-12Rβ1 Psoriasis, 
Behcet’s 
disease, primary 
biliary cirrhosis
Immunochip European 
ancestry (5,052)
rs2305743 (0.81), 
rs436857
SSc Stimulates IFN 
production and TH1 
differentiation
(71)
20 IRAK1 SLE Cohort 
meta-analysis
European 
ancestry (4,873)
rs1059702*TT (1.43) dcSSc, ATA, 
SSc-related 
fibrosis alveolitis
Influence T-cell 
receptor signaling 
and TLR activation. 
Regulator of 
NFκB by way of X 
chromosome
(42, 48, 72)
21 IL-21 RA, SLE, 
DM-type 1, 
Graves’ disease, 
celiac disease
Case–control European 
ancestry (4,493)
rs6822844 (0.86), 
rs907715 (0.91), allelic 
combination: rs2069762* 
A- (1.06), rs6822844* 
T- (0.97), rs6835457*G- 
(0.93), rs907715* T 
(0.91), rs6822844* T 
(0.84)
lcSSc, ACA+, 
global SSc, 
dcSSc, lcSSc, 
protection: SSc, 
lcSSc, and 
ACA+
B-cell differentiation 
and regulates TH17 
development
(65)
(Continued)
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No. Non-HLA-
associated 
genes
Other diseases 
identified
Study type Population 
(n = SSc)
Polymorphism/SNPs 
(OR)
Disease 
association
Proposed  
function
Reference
22 TNIP1 RA, SLE, 
psoriatic arthritis
GWAS cohort European 
ancestry (4,389)
rs9275224 (0.69), 
rs6457617 (0.69), 
rs9275245, rs3130573 
(1.12) located in 
PSORC1C1 gene, 
rs2233287 (1.19), 
rs4958881 (1.19), 
rs3792783 (1.19)
Global SSc, 
global SSc 
except ACA+: 
dependent on 
HLA II, global 
SSc
Negative regulatory 
of NFκB
(48, 73, 74)
23 MIF SLE, psoriatic 
arthritis, 
Lofgren’s 
syndrome, 
inflammatory 
bowel disease
Cohort European 
ancestry (4,286)
MIF-173 (1.10) dcSSc Activates innate 
immunity and 
sustains cellular 
response
(60, 75)
24 NFkβ1 Behcet’s 
disease, Grave’s 
disease, 
Hashimoto 
thyroiditis
GWAS European 
ancestry (4,156)
rs1598859 (1.19) SSc Controls 
inflammation, 
transcription 
regulator
(66, 76)
25 CD226 SLE, DM-type 
1, multiple 
sclerosis
Cohort European 
ancestry (4,131)
rs763361* T (1.02), 
rs34794968 (0.90), 
rs727088 (1.02)
dcSSc, ATA+, 
ILD, pulmonary 
fibrosis
Co-stimulator of 
T cells and T-cell 
adhesion
(77–80)
26 PPARγ RA, psoriatic 
arthritis, 
DM-type 1
GWAS European 
ancestry (3,989)
rs310746 (1.28) SSc Blocks TGF-β, 
mediated fibrosis
(81–83)
27 ITGAM SLE Case–control 
cohort 
meta-analysis
European 
ancestry (3,735)
rs1143679* A (1.12) SSc Regulates neutrophil 
and monocyte 
cell activation 
and adhesion. 
Phagocytosis of 
complement-coated 
particles
(47, 84, 85)
28 TNFAIP3 SLE, RA, celiac 
disease, multiple 
sclerosis
Cohorts 
case–control
European and 
Asian ancestry 
(3,365)
rs5029939* G (2.08), 
rs6932056 (1.69), 
rs117480515* A (3.20), 
rs117480515* A (3.94)
dcSSc, fibrosing 
alveolitis, 
PAH, SSc, 
polyautoimmune 
subset
Regulate immune 
system signaling by 
regulating ubiquitin
(43, 48, 68, 
86)
29 IRF7 SLE Case–control European 
ancestry (2,316)
rs1131665 (0.87) ACA Regulate IFN-gene 
expression and 
inflammatory 
cytokine production. 
Stimulate TLR 
expression
(87)
30 IL-23R Inflammatory 
bowel disease, 
psoriasis, AS
Case–control US – multi-
ethnic and 
European 
ancestry (2,134)
rs11209026*GG 
(0.81), (Arg381 Gln), 
rs11465804*TT (0.83)
ATA, protection 
against PAH, 
dcSSc, ATA, 
protection 
against PAH
Promotes TH17 
expansion
(28, 88, 89)
31 TLR2 Inflammatory 
bowel disease, 
multiple 
infections
Cohort European 
ancestry (1,170)
rs5743704 (2.24), (Pro63 
His)
dcSSc, ATA+, 
PAH
Pathogen recognition 
and direct immune 
response
(90)
32 CD87(UPAR) Vascular 
disease, 
paranasal 
disease
Cohort European 
ancestry (732)
rs344781*GG (1.96) SSc-associated 
digital 
ulceration, PAH, 
ACA, dcSSc, 
lcSSc
Promotes 
extracellular matrix 
and vascular 
remodeling
(91)
33 PLD4 RA Cohort Japanese (730) rs2841277 (1.29), 
rs2841280* G (1.29), 
(minor)
lcSSc, dcSSc, 
protective SSc
Phagocytosis of 
microglia
(68)
34 MMP-12 Kidney disease, 
skin diseases, 
arthro-sclerosis
Cohort Italian ancestry 
(250)
rs2276109*AA (2.44) dcSSc, lcSSc, 
ATA+, pulmonary 
fibrosis
Inhibits endothelial 
cell proliferation and 
angiogenesis
(92)
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ACA, while DQB1*06:11 was associated with ATA positivity and 
a marginal association with pulmonary fibrosis. DQB1*03:01 
had an increase frequency of anti-U1RNP positivity in Chinese 
patients with SSc (26).
The role of HLA II in Italian and Spanish SSc patients 
has also been examined. HLA-DRB1*1104, DQA1*0501, and 
DQB1*0301 haplotypes are overexpressed in this patient popu-
lation (30). Carrying the HLA-DQB1*03 and HLA-DRB1*11 
alleles are risk factors for developing SSc in this subset of 
patients. Having the HLA-DRB1*0701 allele was protective 
(30). HLA-DRB1*1104 allele has association with ATA, while 
HLA-DQB1*0501 in ATA patients is protective (30). ACA-
positive patients expressed HLA-DRB1*01 and -DQB1*05. 
Patients who had pulmonary fibrosis were found to have an 
association with DRB1*11 (32).
HLA-A*30 and -DQB1*04 alleles were found to relate to SSc 
susceptibility in a subset of Brazilian patients (16). In patients 
who had PAH, HLA-B*35, and C*04 were associated as risk 
genes for this complication, while C*03 was protective (16). 
HLA-DRB1*15:02 and DRB5*01:02 are associated with ATA 
positivity in SSc Thai patients. There were no associations seen 
between these genes and other clinical manifestations of disease 
including pulmonary fibrosis, digital pits, sclerodactyly, myositis, 
or SICCA symptoms. DRB1*04 was protective in this patient 
population (33).
In a population of French SSc patients of European ancestry, 
amino acid sequences 67FLEDR71 shared by HLA-DRB was 
associated with ATA positive and dcSSc. Amino acid sequence 
71TRAELDT77 shared by HLA-DQB1 showed weak association 
in dcSSc patients with positive ATA (29). A higher prevalence of 
SSc has been identified in the Choctaw Indian population in com-
parison to non-full-blooded Choctaws, other Native Americans, 
as well as the general population (18, 19). Multiple genetic loci 
located on chromosome 6 near the HLA complex have been 
identified and may contribute to the high prevalence of disease 
(19). HLA-B35, Cw4, DRB1*1602, DQA1*0501, and DQB1*0301 
are strongly associated with SSc in the Choctaw Indian population 
who present clinically with dcSSc, pulmonary fibrosis, and ATA 
positivity (18).
HLA-B*62 and HLA-DRB1*07 correlate with diffuse skin 
involvement while high skin scores correlate with HLA-
DRB1*11 (17). HLA-B*62 and HLA-Cw*0602 has association 
with pulmonary fibrosis, while HLA-B*13 and HLA-B*65 with 
PAH (17). HLA-B*35 is associated with a high risk of developing 
PAH in systemic sclerosis by influencing the production of 
endothelin-1 (ET-1) and decreasing endothelial nitric oxide 
synthase (eNOS) (18, 20–22). HLA-G is expressed in skin of 
patients with systemic sclerosis. Its presence is associated with 
having lower vascular cutaneous ulcers, telangiectasias, and 
inflammatory arthropathy (23).
Non-HLA-Associated Genes
Multiple studies including GWAS, meta-analysis, and recently 
immunochip array analysis have repeatedly shown that modifica-
tions in CD247, interferon regulatory factor 5 (IRF5), and signal 
transducer and activator of transcription protein 4 (STAT4) genes 
are associated with SSc susceptibility (Table 3). Many autoimmune 
disorders share a common genetic background. Both systemic 
lupus erythematosus (SLE) and SSc share many clinical features 
and genetic components. Disease sample size and lack of statistical 
power limits the ability to determine which genes may contribute 
to autoimmunity. Combined analysis of different autoimmune 
diseases increase sample size and allows for statistical power 
to identify genetic variants that effect disease. Using a GWAS 
pan-meta-analysis approach allows for the detection of new genetic 
susceptibility loci, as determined by Martin et  al. (47). In the 
Martin et al. study, GWAS pan-meta-analysis approach for SSc and 
SLE identified and validated three new susceptibility genes for SSc 
[KIAA0319L, paraxylene–orthoxylene domain containing serine/
threonine kinase (PXK), and JAZF1] (47). Genes related to cellular 
response to IFNγ and the nervous system was overrepresented in 
both SLE and SSc. In SSc, genes related to cell signaling, migration, 
and adhesion were over-represented (47). In this section of the 
review, we will discuss Non-HLA-associated genes reported to be 
associated with SSc. In Table 3, we have listed the non-HLA SSc-
associated genes in order of decreasing SSc sample size analyzed.
Autophagy Protein-5
Autophagy protein-5 (ATG5) is an ubiquitin ligase protein that 
assists in autophagosomal elongation that mediates pathogen 
clearance; allowing for the degradation of unwanted cytoplasmic 
material. It has a role in the development of both the innate and 
adaptive immune system (14). Variations in ATG5 are associated 
with susceptibility in SLE and childhood and adult asthma (14). 
Variants located within ATG5 intron rs9373839 G minor allele 
have been identified as SSc susceptibilities (14). The location of 
this variant may suggest that distant genes may affect downstream 
the function of ATG5.
B-Cell Scaffold Protein with Ankyrin Repeats 1
B-cell scaffold protein with ankyrin repeats 1 (BANK1) exerts 
influence in B-cell receptor-induced calcium mobilization 
from intracellular (IC) stores. It has been identified in SLE as a 
susceptibility gene. There is an increased risk for developing SSc 
with BANK1 haplotype G–C compared to A–T haplotype (35). 
BANK1 variants rs3733197 G alleles, rs10516487, rs10516487*G, 
and rs17266594*T are strongly associated with diffuse dcSSc and 
ATA autoantibodies (36).
B-Lymphocyte Kinase
B-lymphocyte kinase (BLK) encodes B-cell signal transducer and 
functional variant C8orf13-BLK. Disruption in BLK may result 
in abnormal B-cell gene expression and altered NFκB signaling 
(48). C8orf13-BLK has been identified in multiple studies as a 
risk gene for SSc (62–64). C8orf13-BLK variant rs2736340 and 
rs13277113 are associated with SSc and dcSSc (63). An additive 
effect between C8orf13-BLK and BANK1 increases susceptibil-
ity to dcSSc (62). Two haplotype blocks (FAM167A and BLK) 
have also been identified. Allele rs13277113*A in the BLK block 
is significantly associated with SSc (64). This association was 
observed despite autoantibody profile or disease classification 
(dcSSc or lcSSc) (64).
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CD247
CD247 encodes T-cell receptor zeta (CD3ζ), which functions 
in the assembly of TCR–CD3 complex and its transport to the 
cell surface, thereby playing a crucial role in cell signaling (49). 
Variants of CD247 may lead to impaired immune response and 
dysregulation of T-cell activation. CD247 has been associated 
with susceptibility to SLE. CD247 rs2056626 (in addition to IRF5, 
MHC, and STAT4) were identified as susceptibility genes for SSc in 
multiple studies. The G minor allele of this variant has a protective 
effect (49, 69). This variant was not found to have an association 
with SSc or disease subtypes in a Hans Chinese cohort, suggesting 
that the association may be ethnicity-dependent (113).
c-SRC Tyrosine Kinase
c-SRC tyrosine kinase (CSK) is important for cell regulation, dif-
ferentiation, migration, and immune response. CSK inactivates 
src kinases by phosphorylating tyrosine at the C-terminus. In 
fibrosis, srk kinases regulate FAK needed for integrin signaling 
and fibroblast adhesion to extracellular matrix (ECM). Incubating 
fibroblasts with inhibitors of CSK decreases COLIAI and COLIA2. 
Polymorphisms in CSK prevent or inhibit the phosphorylation 
of src leading to fibrosis (70). Polymorphism in the intron of the 
CSK gene is associated with SSc. Variant rs1378942 is associated 
with overall SSc (70).
Deoxyribonuclease 1-Like 3
A member of the human DNase 1 family, deoxyribonuclease 
1-like 3 (DNASE1L3) is secreted by macrophages and is found 
in the liver and spleen (14). During apoptosis, DNASE1L3 has a 
role in the fragmentation of DNA. It also generates double-strand 
breaks in immunoglobulin-encoding genes. In regards to autoim-
mune susceptibility, DNASE1L3 is found to be associated with 
susceptibility to SLE and rheumatoid arthritis (RA). Using the 
immunochip array, DNASE1L3 SNP rs35677470 was identified 
as a risk for SSc and ACA positivity. These authors identified a 
substitution in amino acid Arg to Cys at position 206 on exon 8 
of DNASE1L3 protein resulted in the loss of a hydrogen bond. The 
amino acid substitution in this position may cause the protein to 
become inactive suggesting a potential role for SNP rs35677470 in 
autoimmunity due to defective apoptotic DNA breakdown (14).
interferon-Regulated Genes and PAH
Multiple studies using GWAS, meta-analysis, and immunochip 
analysis assays have confirmed the involvement of IFN in SSc 
susceptibility. The identification of multiple variants in IFN genes 
in association with SSc, SSc lung disease, and SSc mortality high-
lights the significance of the IFN pathway in the development 
and progression of SSc. IFN modulate differentiation, survival, 
proliferation, and cytokine production by T and B cells and 
dendritic cells. IFN stimulate the expression of toll-like receptors 
(TLRs) 3, 7, and 9. IFN genes were overexpressed in peripheral 
blood mononuclear cells (PBMCs) from patients with SSc and 
SLE. Higher IFN scores correlated with ATA, anti-U1RNP, 
lymphopenia, and IFNα/IFNβ receptor 2 (IFNAR2) missense 
mutation rs7279064 GG or GT (114). Other variants in the IFN 
pathway have also been well established in SSc. Polymorphisms 
in IRF5, IRF7, and IRF8 have been identified. IRF5 mediates IFN 
activity and is an important inflammatory signaling pathway. 
Polymorphisms in IRF5 are associated with SLE, RA, ulcerative 
colitis, and others. Regulation in immune reaction to infections 
by IRF5 is activated by TLRs 7 and 9. In SLE, IRF5-transportin-3 
gene (TPO) rs4728142 correlates with IRF5 expression leading 
to increased binding of zinc-finger BD 3 (ZBTB3) affecting 
both RNA transcription and DNA binding (115). In SSc, IRF5 
rs200460 is associated with dcSSc, lcSSc, ATA, and ACA. The 
strongest association is with ATA and ILD (38). It is linked to 
overall mortality independent of disease type or serology (39). A 
Han Chinese cohort of 424 SSc patients identified rs2004640*TT 
genotype as being significant in this population. This variant is 
associated with pulmonary fibrosis and ATA positivity (40). IRF5 
rs4728142 is predictive of longer survival and milder pulmonary 
fibrosis. The association is independent of age of disease onset, 
autoantibody profile, or disease type (41). IRF7: Interferon 
regulatory factor 7 (IRF7) activates type IFN genes in response 
to DNA/RNA immune complexes and viral infections. IRF7 
associates with susceptibility to SLE. Multiple variants in the IRF7 
genes confer susceptibility to SSc. IRF7 rs1131665 is associated 
with SSc-associated ACA positivity. The variants identified were 
replicated in a Spanish cohort (87). IRF8: Multiple studies have 
identified IRF8 association with SSc and rs11642873 with lcSSc 
(24). IRF8 rs2280381 has been identified as SSc susceptible gene 
in a Japanese cohort (68).
Attention has focused on the possible contribution of the 
immune system to pathogenetic processes in PAH, especially 
innate immunity and IFNs (116, 117). Type I IFNs are implicated 
by the association of use of IFNα in the treatment of hepatitis 
and of IFNβ in the treatment of multiple sclerosis (MS) with 
development of PAH (118, 119). Diseases in which there is an 
“IFN signature” (such as SLE, SSc, and infection with HIV) are 
associated with development of PAH (120–124). Furthermore, 
IFNα and IFNγ added to cultures of human pulmonary artery 
smooth muscle cells (PASMC) primed with TNFα or to cultures 
of human lung MVEC or human lung fibroblasts, cause release of 
the potent vasoconstrictor, ET-1, and of IFN-inducible protein-10 
(IP-10) (117). In a series of 128 SSc patients with PAH and 35 
patients with no PAH, the SSc patients with PAH had higher levels 
of IP-10 and ET-1 in their sera compared to SSc patients without 
PAH or compared to healthy controls. More SSc patients with 
PAH had detectable levels of IFNα and IFNγ in their sera than 
SSc patients without PAH (117). In this series of SSc patients, 
levels of TNFα, IL-12p70, IL-6, IL-1α, and IL-8 were significantly 
higher in sera in SSc patients with PAH when compared to SSc 
patients without PAH (117). Additional studies of this patient 
group revealed that serum levels of IP-10 in the SSc-PAH patients 
correlated with pulmonary vascular resistance, and levels of brain 
natriuretic peptide in serum, and serum IP-10 levels in the SSc-
PAH patients inversely correlated with cardiac index and 6-min 
walks test (117). Sections of lung from patients with idiopathic 
PAH (IPAH) or with SSc-PAH expressed higher levels of type I 
interferon receptor 1 (IFNR1) in endothelium, smooth muscle 
layer, vascular interstitium, and in intravascular inflammatory 
cells as assessed by immunohistochemistry and Western blot-
ting (117). While the above studies strongly implicated type I 
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IFN as playing a pathogenic role in SSc-PAH and IPAH, further 
evidence was substantiated in the type I interferon α receptor 1 
knockout mouse which was found to be resistant to experimental 
hypoxic PAH induction. These mice did not have elevated serum 
levels of ET-1 when compared to wild-type (WT) control mice 
(117). Analysis of PBMC from patients with SSc revealed CD169/
sialoadhesin (Siglec-1) and other IFN-regulated genes were over-
expressed in patients with dcSSc, whereas patients with lcSSc with 
PAH overexpressed IL-13RA1, intercellular adhesion molecule-1 
(ICAM-1), C–C chemokine receptor type 1 protein or gene (CCR1), 
JAK2, and melanocortin receptor 1 (MCR1) (123, 125, 126). IL-13 
was also elevated to higher levels in sera of patients with lcSSc 
with PAH, and MCR1 was induced on CD14+ monocytes sug-
gesting monocytes are activated in lcSSc patients with PAH of 
an alternative (i.e., IL-4/IL-13) rather than classical [i.e., IFNγ/
lipopolysaccharides (LPS)] pathway (123). The identification of 
multiple IFN genes having association in SSc, SSc lung disease, 
and mortality highlights the significance of the IFN pathway in 
the development and progression of SSc.
interleukin-1 Receptor Associated Kinase 1
Interleukin-1 receptor associated kinase 1 (IRAK1) gene is located 
on the Xq28 and is in the same haplotypic block with methyl-
CpG-binding protein 2 gene (MECP2). IRAK1 encodes a serine/
threonine protein kinase that regulates NFκB through T-cell recep-
tor signaling and TLRs/IL-1R activation. It also plays a role in IFN 
induction. IRAK1 has been identified in SLE as a susceptibility 
gene (42, 72). In SSc, IRAK1 rs1059702*TT is associated with 
dcSSc, SSc-related fibrosing alveolitis, and ATA positivity (42, 72). 
The presence of the T allele may contribute to disease severity, and 
presence of MECP2 rs17435 may explain the association of IRAK1 
variant rs1059702 with this subset (42, 72).
iL-2/iL-12 Genetic Susceptibility
Variants in interleukin-2 receptor α (IL-2A), IL-12R (IL-12Rβ1 
or IL-12Rβ2) have been reported to be associated with SSc. IL-2 
plays a role in immune system homeostasis and self-tolerance. 
It facilitates B-cell immunoglobulin production and induces 
natural killer cell proliferation and differentiation (65). The 
binding of IL-12 to its receptors stimulates IFN production 
and promotes TH1 differentiation. IL-12 signals through 
STAT pathway and a defect in either STAT4 or IL-12R could 
influence SSc pathogenesis. Variant SNP rs77583790 found 
in the intergenic region between SCHIP1 and IL-12A was 
found to be associated with lcSSc (14). IL-12Rβ1 and IL-12Rβ2 
recruit tyrosine kinases and activate transcription of other 
genes. Polymorphisms in IL-12Rβ1 and IL-12Rβ2 have been 
identified in psoriasis, Behcet’s disease, and primary biliary 
cirrhosis (67). Two studies were conducted to investigate the 
role of IL-2 in SSc. ILR2 gene variants: rs11594656, rs2104286, 
and rs12722495 were associated with SSc, lcSSc, and ACA 
positivity. The associations are strongly dependent on ACA 
since removal of ACA from the analysis resulted in loss of 
association, and the strongest association with ACA positivity 
was with rs2104286, with associations of the other IL-2 RA 
gene variants being lost after conditioning to rs2104286 (66). 
Polymorphism in rs2104286 has the strongest association with 
ACA while rs6822844 and rs907715 have association with SSc 
and lcSSc (66). IL-12Rβ1 rs2305743 and rs436857 were found to 
be associated with SSc (71). Polymorphisms in these receptors 
may affect the binding of transcription factors decreasing the 
expression of IL-12. IL-12Rβ2 rs3790567 is associated with 
SSc. IL-12Rβ2 gene maps close to the IL-23 coding region, the 
association between rs3790567 was not found to be dependent 
on IL-23 (67). IL-2/IL-21: IL-21 affects the innate and adap-
tive immune response playing a role in the differentiation of 
B cells into plasma cells and regulation of TH17 development 
(65). Polymorphism in the IL-2/IL-21 region is associated with 
lcSSc and global SSc. IL-2/IL-21 variant rs682284 is strongly 
associated with multiple autoimmune diseases and is considered 
an autoimmune susceptibility locus (127). The rs907715 minor 
allele and rs682284 have association with SSc. Variant rs6822844 
influences lcSSc and ACA positivity (65). The allelic combina-
tion of rs2069762*A–rs6822844*T–rs6835457G–rs907715*T is 
associated with dcSSc and lcSSc (65). The T allele for rs6822844 
acts as a protective for lcSSc and ACA positivity.
iL-23
IL-23 promotes the expansion of TH17. IL-17 and IL-23 are 
elevated in the plasma of SSc patients (28). Polymorphism in 
IL-23R is associated with SSc and ATA positivity. IL-23R variant 
rs11209026*GG (Arg381 Gln variant) has association with ATA 
positivity and rs11465804*TT is associated with dcSSc and ATA 
positivity. The major alleles rs11209026*G and 11465804*T were 
decreased in patients with PAH, suggesting that the major allele 
is protective against PAH (28).
integrin αM
Integrin αM (ITGAM) β2 is a leukocyte-specific integrin that 
regulates neutrophil and monocyte cell activation and adhesion. 
It allows for phagocytosis of complemented-coated particles. 
Deficiency in ITGAM results in increased IL-6 production by 
antigen-presenting cells (APC) (128). Pooled meta-analysis, 
subsequent independent meta-analysis, and GWAS looking at 
shared risk polymorphisms for SLE and SSc confirmed ITGAM 
variant rs1143679 were associated with susceptibility to SSc (47, 
84, 128).
Juxtaposed with Another Zinc-Finger 1
Juxtaposed with another zinc-finger 1 (JAZF1) encodes a nuclear 
protein with zinc-fingers that functions to repress transcription. It 
has been associated with bone morphogenesis and CI deposition 
(47). JAZF1 has been identified as an SLE-associated locus, and a 
recent GWAS pan-meta-analysis has confirmed JAZF1 rs1635852 
association with SSc (47).
KiAA03192L
KIAA03192L has been identified in polycystic kidney disease and 
dyslexia as a disease susceptibility gene. It is expressed in mac-
rophages and natural killer cells in mice and in CD33+ myeloid cells 
and CD14+ monocytes in humans. KIAA03192L is overexpressed 
in PBMCs of SLE patients. In SSc, KIAA03192L variant rs2275247 
is associated with lcSSc (47).
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Protein Tyrosine Phosphatase Non-Receptor 
Type 22
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) 
plays a critical role as a gatekeeper for T-cell receptor signaling. 
It encodes the protein tyrosine phosphatase lymphoid tyrosine 
phosphatase in T-cells and acts to inhibit T-cell signaling through 
dephosphorylation of substrates. Polymorphism in PTPN22 has 
been associated with type 1 DM, RA, and SLE. Earlier studies look-
ing at the relationship between PTPN22 and SSc failed to show an 
association between PTPN22 and SSc (129, 130). Larger studies in 
SSc patients showed association with PTPN22 Ct/TT genotypes 
with both ATA and ACA positivity. The T allele associated with ATA 
positivity and the CC genotype with both ACA and ATA positivity 
(55). Meta-analysis confirmed PTPN22 rs2476601*T and the minor 
allele 1858T are associated with SSc and ACA positivity (56, 57). 
Haplotype 1858C allele was protective in a French cohort (58).
Paraxylene–Orthoxylene (Phox Homology) 
Domain Containing Serine/Threonine Kinase
Paraxylene–Orthoxylene domain containing serine/threonine 
kinase is a protein that plays a role in the ligand-induced inter-
nalization, degradation, and trafficking of epidermal growth 
factors. Variation in PXK is association with SLE susceptibility 
where it is found to alter B-cell receptor internalization (131). PXK 
rs2176082 and rs4681851 are associated with SSc and rs2176082 
has association for ACA positivity. The association of rs2176082 
is related to DNASE1L3 (14, 47).
Signal Transducer and Activator of Transcription 
Protein 4
Signal transducer and activator of transcription protein 4 is 
critical for T-cell signaling and differentiation (132–134). STAT4 
is involved in effecting a Th1 cytokine response by transmitting 
signals from IL-2, IL-12, and IL-23 receptors and in signaling after 
type 1-IFN engages its receptor (135, 136). The role of STAT4 in 
fibrosis was assessed in scleroderma mouse models. To assess the 
contribution of STAT4 to bleomycin (BLM)-induced skin fibrosis 
and fibrosis of skin in (tight skin) Tsk-1/+ mice, BLM was injected 
for 3  weeks into STAT4–/– and STAT4+/+ mice. STAT4–/– mice 
were crossed with Tsk-1/+ mice, and skin fibrosis was assessed 
(137). The deletion of STAT4 significantly reduced skin fibrosis 
in the BLM model but not in the Tsk-1/+ model (137). In the 
BLM model, it was noted that there were decreased numbers of 
inflammatory cells including T cells and proliferating T cells and 
decreased quantity of IL-6, IL-2, TNFα, and IFNγ in lesional skin 
of STAT4–/– vs. STAT4+/+ mice (137).
Signal transducer and activator of transcription protein 4 is 
considered an autoimmunity loci since its association has been 
firmly confirmed in SLE, RA, primary biliary cirrhosis, and SSc 
(48). SNP rs7574865 is associated susceptibility to lcSSc and ACA 
positivity (50, 51). SNP rs7574865 and rs10168266 were associated 
with dcSSc, ATA positivity, and pulmonary fibrosis in a Chinese 
cohort (52). Variant rs7574865*T allele has an additive effect with 
IRF5 rs2004640 seen in fibrosing alveolitis (38). Gene–gene inter-
actions between STAT4 and polymorphism in the transcription 
factor T-bet show increased susceptibility to SSc. Transcription 
factor T-bet [(T-box expressed in T cells) (TBX21)] is an important 
transcriptional activator of Th1 differentiation effecting Th1/Th2 
balance. Polymorphisms in TBX21 have associations with RA, 
asthma, and type 1 DM. TT genotype of TBX21 variant rs11650354 
confers susceptibility to SSc in a recessive manner while STAT4 
variant rs11889341 A allele is associated with an increased risk 
of SSc in a dominant pattern. STAT4 genotype increased the SSc 
risk in the presence of TBX21 CC genotype (53). Plasma levels 
of circulating IL-6 and TNF were increased in SSc patients who 
carry the TBX21 CC genotype where as those who carry the TT 
genotype show increased circulating IL-2 and IL-5 suggesting 
that patients who carry the CC genotype have a prominent pro-
inflammatory cytokine profile (53). Gene expression profile from 
whole blood RNA of SSc patients suggest a role for type 1-IFN and 
pro-inflammatory cytokines in the CC genotype and of the T-cell 
pathway in the TT group (53).
Tumor Necrosis Factor Alpha-induced Protein-3
Tumor necrosis factor alpha-induced protein-3 (TNFAIP3) 
encodes ubiquitin-modifying protein A20 and has a critical role 
in the regulation of immune signaling pathways.
Polymorphism in TNFAIP3 is associated with SLE, RA, and 
celiac disease. TNFAIP3 rs117480515, rs5029939*G allele, and 
rs6932056 carry an increase of susceptibility to SSc (43, 68). 
TNFAIP3 SNP and rs5029939*G is associated with dcSSc, fibrosing 
alveolitis, and PAH (43). The rs117480515*A allele is associated 
with SSc polyautoimmune subset (86).
Tumor Necrosis Factor Superfamily Member 4 
Gene
Tumor necrosis factor superfamily member 4 gene (TNFSF4) 
encodes for the T-cell co-stimulatory molecule, OX40 ligand. 
TNFSF4 has a role in B-cell proliferation and differentiation 
and T-cell proliferation. Ox40–OX40L promotes generation 
of Th2 cytokines. It has been identified as a susceptibility gene 
for SLE. TNFSF4 SNPs variant rs1234314, rs2205960, rs844648, 
rs12039904, rs1234317, and rs10912580 have been identified as 
susceptibility genes in SSc and are associated with lcSSc- and 
ACA-positive SSc patients in multiple French European studies 
(120–122). The minor allele rs1234314 has association for lcSSc, 
ACA, and ATA, while rs844648 confirmed association with dcSSc 
and ARA. Variant rs844648 was found to be protective in all SSc 
sub-groups except ARA+. In women, rs2205960*TT/GT and 
rs844648*AA associates with increased risk for SSc (59). These 
studies suggest TNFSF4 as a susceptibility gene for SSc.
TNFAiP3 interacting Protein-1
TNFAIP3 interacting protein-1 (TNIP1) gene interacts with A20 
binding protein (BP) and inhibits TNF-induced NFκB-dependent 
gene expression; thereby negatively regulating NFκB. Mutations 
in this gene have been associated with RA, SLE, and psoriatic 
arthritis. TNIP1 gene and protein expression was reduced in 
lesional skin tissue and cultured fibroblasts from SSc patients. 
In vitro, TNIP1 had inhibitory effects on inflammatory cytokine-
induced CI production (73). TN1P1 SNP rs2233287, rs4958881, 
and rs3792783 are associated with global SSc (74). A two-staged 
GWAS showed strong linkage disequilibrium in the HLA-DQB1  
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gene: rs9275224, rs6457617, and rs9275245. Within the MHC 
region, there was association with rs3130573 located in the 
PSORC1C1 gene. PSORS1C1 also show susceptibility in global SSc 
except for ACA positivity patients but this association is dependent 
on HLA class-II (74).
CD87 (UPAR)
Urokinase-type plasminogen activator receptor (UPAR) promotes 
ECM and vascular remodeling. It regulates growth factor activation 
and is responsible for cell adhesion, migration, and proliferation 
(91). UPAR rs344781*G allele is associated with SSc-related digital 
ulcers, pulmonary artery hypertension, ACA positivity, and lcSSc 
(91). Genotype rs344781*GG is identified as an independent risk 
factor for SSc-related digital ulcers and PAH (91). CD226: acts as 
a co-stimulator of T cells and plays a role in T-cell adhesion. It is 
expressed on NK cells, monocytes, platelets, and B and T cells (77). 
It has been correlated with susceptibility to SLE, type 1 diabetes, 
thyroid disease, and MS (78–80). In SSc, the CD226 T allele of 
rs763361 may contribute to disease severity due to its association 
with multiple SSc subsets including dcSSc, ATA positivity, and ILD 
(80). CD226 haplotype SNP rs763361, rs34794968, and rs727088 
correlates with pulmonary fibrosis (77). MIF: Macrophage migra-
tion inhibitory factor (MIF)-173 acts upstream, activates innate 
immunity, and sustains cellular and inflammatory responses. MIF 
induces endothelial adhesion and induces fibroblast proliferation 
that may contribute to vasculopathy (135). MIF-173 is lower 
in lcSSc. In  vitro, C7 MIF encoded fibroblasts produced more 
MIF than non-stimulated fibroblasts (75). In an American and 
European study that included 3,800 SSc patients, MIF was found 
to have higher association with dcSSc compared to controls and 
lcSSc (75, 138). MMP-12: matrix metalloproteinase-1 (MMP-1) 
rs2276109*AA genotype has significant association in dcSSc, lcSSc, 
ATA positivity, and pulmonary fibrosis in an Italian SSc population 
(92). NFkB1 gene SNP rs1598859 is associated with overall SSc 
disease (70). PLD4: phospholipase D family member 4 (PLD4) was 
identified as a susceptibility gene for SSc in Japanese (68). PPARγ: 
peroxisome proliferation-activated receptor gamma (PPAR-γ) 
when engaged by ligands of different types blocks transforming 
growth factor (TGF)-β mediated fibrotic responses in vitro in cul-
tured fibroblasts and in various fibrotic animal models in vivo (81, 
82). PPARG rs310746 is associated with SSc (83). PSD3: involved 
in signal transduction pathways and IC signaling. Polymorphism 
in the PSD3 gene rs10096702 is associated with overall SSc (70). 
TLR2: subcutaneous injections of TLR ligands into the skin of SSc 
results in a significant inflammatory reaction resulting in SSc skin 
changes (90). TLR2 pro63 His is associated with dcSSc, PAH, and 
ATA positivity (90). TLR5 and 10 expression were increased in 
SSc fibroblasts in vitro and in vivo (139).
Vascular Related Genes
Endothelin-1 is one of three isoforms and is synthesized by 
vascular endothelial (VE) cells, fibroblasts, bone marrow mast 
cells, neutrophils, macrophages, and cardiac myocytes (140). 
Various triggers induce synthesis of ET-1 including TGF-β and 
other growth factors, cold exposure, low shear stress, hypoxia, and 
angiotensin II (140); but its synthesis is reduced by nitric oxide 
(NO), natriuretic peptides, increased blood flow, and prostacyclin 
(141). ET-1 is also degraded by MMP-1, which is reduced in 
SSc (140). Two types of receptors for ET-1 (ETα and ETβ) are 
variably expressed on endothelial cells, vascular smooth muscle 
cells, adventitial fibroblasts, tissue fibroblasts, neutrophils, mast 
cells; and monocytes and ET receptor engagement on these cells 
triggers a variety of pro-inflammatory or fibrotic response, includ-
ing vasoconstriction of vasculature (140). ET-1 increases surface 
expression of ICAM-1 on fibroblasts, stimulates CI synthesis, 
promotes formation of myofibroblasts, and facilitates binding 
of T cells to fibroblasts (140, 142). ET-1 acts as a downstream 
mediator of TGF-β, and its induction by TGF-β in fibroblasts is 
via small mother against decapentaplegic (Smad)-independent 
signaling that involves c-Jun N-terminal kinase (JNK) and activin 
receptor-like kinase (ALK)5 pathways (143). Polymorphisms of 
ET-1 receptors are associated with SSc. For example, there is an 
association of EDNRB polymorphisms and dcSSc and EDNR-A 
polymorphism with anti-RNA polymerase autoantibodies in SSc 
(140). Polymorphisms were also described in the promoter of 
the NOS2 gene that confers susceptibility to PAH in SSc (144). 
Potassium voltage-gated channel shaker-related subfamily 5 
(KCNA5) has a role in the regulation of vascular tone. It is inhibited 
by hypoxic conditions leading to vasoconstriction. KCNA5 may 
have a protective role against PAH-associated SSc, this protective 
role was identified with variant rs10744676 (145).
MicroRNAs
MicroRNAs are translational regulators of gene expression and 
also destabilize messenger RNAs (mRNAs) of target genes (146). 
MiRNAs are tissue- and cell type-specific short, single-stranded 
non-coding RNAs that function to modulate gene expression 
(Table 4). MiRNA bind to the 3ʹ untranslated region of mRNA of 
the target gene and mediate post-transcriptional regulation. Once 
bound, they either cause translational repression of the target 
gene or induce the degradation of the gene (147–149). In SSc, 
several miRNAs are associated with TGF-β and CI expression. In 
comparison to normal skin tissue, Zhu et al. (93, 147) found that 
skin from patients with lc and dc SSc expressed miR-21, miR-31, 
miR-146, miR-503, miR-145, and miR-29b. In these patients, 
miR-21 was increased in both tissue and fibroblasts whereas miR-145 
and -29b were decreased. These miRNAs targeted the TGF-β path-
way – including Smad7, Smad3, and COL1A1. TGF-β stimulation 
resulted in increased miR-21 expression and decreased expression 
of Smad7, while the upregulation of miR-145 was associated with a 
downregulation of Smad3 message. These same authors found that 
overexpressing miR-21 in fibroblasts decreased Smad7 but knocking 
down the expression of miR-21 increased Smad7 expression (93). 
miR-21 was also found to have increased expression in BLM-induced 
skin fibrosis. Reporter gene assay analyses revealed that the target 
gene for miR-21 is Smad7, while the target gene for miR-145 is Smad3 
(93, 94).
Ninety-five miRNAs were analyzed in the sera of SSc patients 
and healthy controls. This analysis revealed that miR-30b was sig-
nificantly downregulated in SSc patients and the modified Rodnan 
skin score (MRSS) inversely correlated with the level of miR-30b 
(95). Downregulation was also seen in the skin of scleroderma 
patients and BLM-treated sclerotic skin (95). Transfection studies 
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showed that miR-30b affects platelet-derived growth factor/
receptor (PDGFR)-β expression by suppressing this receptor (95). 
In their evaluation of 15 SSc patients and 15 normal subjects, 
Koba et  al. (150) found that miR-206 and miR-21 were useful 
in distinguishing patients with SSc from normal subjects (150).
miRNA-Targeting Ci
The expression of miR-196a was investigated in SSc both in vitro 
and in vivo. In vivo miR-196a was detected in the serum of SSc 
patients. Patients who had measurable lower levels of miR-196a 
had dcSSc compared to lcSSc. Lower levels of miR-196a was also 
associated with higher prevalence of pitting digital scars and more 
fibrotic skin as measured by MRSS (99). In vitro, the expression 
of miR-196a was normalized by TGF-β small interfering RNA 
(siRNA) in SSc fibroblasts, and the addition of miR-196a inhibitor 
to these fibroblasts resulted in the downregulation of CI. When the 
inhibitor was added to normal fibroblasts, there was an overexpres-
sion of CI (99). These results suggest that miR-196a may regulate 
CI expression.
Micro-RNA-29 (miR-29) is a TGF-β associated miRNA and is 
linked to fibrosis likely by interaction with several extracellular 
genes including ELN, FBN1, COL1A, COL1A2, and COL3A1 
(151, 152). TGF-β/Smad3 signaling appears to negatively 
regulate miR-29 (153). Support for this relationship was the 
finding that in BLM pulmonary fibrosis mouse model, Smad3 
was upregulated while miR-29 was downregulated in contrast 
to results with Smad3–/– mice, which were protected from BLN 
pulmonary fibrosis and miR-29 was upregulated (153). In addi-
tion, therapeutic delivery of miR-29 to mice using Sleeping 
Beauty transposon-mediated gene transfer protected mice from 
developing BLM-induced lung fibrosis (153). MiR-29a has the 
ability to bind to the 3ʹUTR of COL1A1 and COL1A2 (96, 154). 
Maurer et al. (97) found that miR-29a was strongly downregulated 
in SSc fibroblasts and skin sections when compared to healthy 
controls (97). SSc fibroblasts, in which miR-29 was overexpressed, 
exhibited decreased expression and protein levels of CI and CIII, 
while knockdown of miR-29 in normal fibroblasts increased CI 
production. Levels of miR-29 were reduced in normal fibroblasts 
when these fibroblasts were cultured with TGF-β, PDGF-β, or 
IL-4 (97). These studies confirm that miR-29a directly regulates 
CI. Serum levels of miR-29a were investigated to determine its 
potential role as a biomarker in SSc. In 61 patients with SSc, 
approximately 40% of which had dcSSc, miR-29a was found to 
be upregulated and not downregulated as expected in the serum of 
these patients. Patients with scleroderma spectrum disorder (SSD) 
are those who did not fulfill the ACR diagnosis criteria for SSc 
but who may develop scleroderma in the future. In these patients, 
miR-29a was downregulated compared to healthy controls, dcSSc, 
and lcSSc patients (96). Decreased serum levels of miR-29a may 
also be associated with higher right ventricular systolic pressure 
and PAH (96).
MiR-150 expression is decreased in SSc fibroblasts and sera. 
Normal fibroblasts that were transfected with miR-150 inhibi-
tor had induced expression of type 1 CI, pSmad3, and integrin 
(101). Forced expression of miR-150 in SSc fibroblasts resulted 
in downregulation of CI, pSmad3, and integrin (101). In patient 
sera, lower expression of miR-150 correlated with severe clinical 
disease (101).
Skin and fibroblasts from localized scleroderma showed 
decreased levels of miR-7 compared to keloid skin and normal skin 
in vivo and in vitro (102). Normal fibroblasts that were transfected 
with miR-7 inhibitor exhibited upregulation of COL1A2 (102).
Skin and sera from SSc and localized scleroderma patients 
showed a downregulation of miR let-7a when compared to normal 
and keloid skin (104). CI was reduced by the overexpression and 
inhibition of miR let-7a in human and mouse skin fibroblasts 
(104). Intermittent overexpression of miR let-7a by intraperitoneal 
injections reduced dermal fibrosis in the BLM skin model (104).
MiR-129-5p is a regulator of COL1A1 (154) and is down-
regulated in SSc (105). Nakashima et  al. (105) found that, in 
their 20 patients with SSc, IL-17A expression was increased in 
the involved skin and sera, but IL-17R type A was decreased 
in SSc fibroblasts when compared to normal (105). IL-17A 
reduced protein expression of type I CI α1 chain [α1(I)] and 
connective tissue growth factor (CTGF). IL-17A also induced 
the expression of miR-129-5p (105). In the presence of IL-17A, 
miR-129-5p is increased with α1(I) and CTGF. The authors 
suggest that since SSc fibroblasts have intrinsic activation of 
TGF-β, TGF-β suppresses IL-17A, in addition to miR-129-5p 
with resultant CI accumulation (105).
TABLe 4 | MicroRNAs in SSc.
Micro RNA (miR) implications for SSc 
pathogenesis
Reference
miR-21 ↑ in SSc skin and 
fibroblasts
↑ by TGF-β, ↓ Smad7 (93, 94)
miR-145 ↓ in SSc skin 
and fibroblasts
Smad3 is its target gene (93, 94)
miR-29b ↓ in SSc skin 
and fibroblasts
Suppressor of fibrosis (94)
miR-30b ↓ in SSc skin 
and fibroblasts
Suppressor of PDGFR-β (95)
miR-29a ↓ in SSc sera 
and skin
Suppressor of CI and CIII synthesis 
by fibroblasts, miR-29a is reduced 
by TGF-β, PDGF-β, and IL-4. Lower 
serum miR-29a associates with PAH
(96–98)
miR-196a ↓ in dcSSc  
sera
Expression of miR-196a reduced by 
TGF-β. May regulate CI synthesis. ↓ 
miR-196 = ↑ MRSS, ↑ digital pitting, 
and scars
(99, 100)
miR-150 ↓ in SSc 
fibroblasts and sera
Reduces fibroblast CI, pSmad3, and 
integrin expression
(101)
miR-7 ↓ in localized 
scleroderma skin and 
fibroblasts
Reduces CI synthesis by fibroblasts. 
Regulated by TSP2
(102, 103)
miR-let-7a ↓ in SSc and 
localized scleroderma skin 
and sera
Reduces CI synthesis by fibroblasts (104)
miR-129-5p ↓ in SSc Suppressor of COL1A1 expression 
in fibroblasts
(105)
miR-142-3p ↑ SSc in sera May regulate αV integrin, which 
may recruit and activate small latent 
complex that regulates autocrine 
TGF-β activity
(106)
miR-92a ↑ in SSc sera 
and fibroblasts
May downregulate MMP-1 (107)
miR-21 ↑ SSc in 
fibroblasts
miR-21 is upregulated by TGF-β and 
decreases expression by Smad7
(93, 94)
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MicroRNA-29a and miRNA-196a are low in SSc fibroblasts 
and can suppress CI gene expression, suggesting the low-level 
expression of the miRNAs permit CI to be upregulated by TGF-β 
and other mediators in SSc fibrogenesis (97, 99). Levels of other 
miRNAs have been found to differ in patients with SSc compared 
to healthy controls as follows: serum miR-142-3p was higher in 
SSc patients than healthy controls (106); levels of miR-21 were 
increased, whereas levels of miR-145 and miR-29b were decreased 
in SSc lesional fibroblasts (94); miR-92a is more elevated in sera 
and SSc lesional fibroblasts than in normal healthy controls and 
may downregulate MMP-1 (107); and levels of miRNA-7 were 
found to be reduced in sera and lesional fibroblasts from patients 
with localized scleroderma and may regulate CI expression 
(102). MiR-150 regulates β3 integrin expression and was found 
to be downregulated in lesional SSc dermal fibroblasts compared 
to healthy donor fibroblasts (101); miR let-7a was found to be 
decreased in sera and lesional fibroblasts from patients with SSc 
or localized scleroderma (104); and miR-21 was found to be 
upregulated in SSc lesional dermal fibroblasts (93).
Discoidin domain receptor 2 (DDR2) and thrombospondin-2 
(TSP2) were both found to be decreased in SSc dermal fibroblasts 
(103, 104). In SSc dermal fibroblasts, DDR2 mRNA and protein 
levels were suppressed, but the knockdown of TGF-β in these 
fibroblasts resulted in increased expression of DDR2 (104). 
In normal fibroblasts, DDR2 knockdown increased miR-196a 
expression with resultant decrease in CI. This was not seen 
when DDR2 was knocked-down in SSc fibroblasts (104). In SSc, 
fibroblasts, knocking down DDR2 did not affect TGF-β signaling 
or miR-196a expression, suggesting that intrinsic expression of 
TGF-β causes the downregulation of DDR2 in SSc fibroblasts 
(104).
Thrombospondin 2 mRNA expression and protein levels are 
decreased in SSc fibroblasts when compared to controls but were 
upregulated in conditioned medium from SSc fibroblasts (103). 
Knockdown of TSP2 in dermal fibroblasts caused decreased 
expression of CI and increased miR-7 expression (103). SSc dermal 
fibroblasts show an increased expression of miR-7 (103) suggesting 
that a negative feedback mechanism may exist between TSP2 and 
miR-7 (103).
Matrix metalloproteinase-1 was downregulated when normal 
dermal fibroblasts were overexpressed with miR-92a (107). In 61 
patients with SSc, medium serum levels of miR-92a were elevated. 
This upregulation was constitutively also found in SSc dermal 
fibroblast, but when these fibroblasts were transfected with siRNA 
of TGF-β, the expression of miR-92a was decreased (107). These 
studies suggest that miR-92a ability to affect MMP-1 suggest that 
miR-92a may be a target for MMP-1.
Hair miRNA
MicroRNA from the hair shaft and roots was studied. Hair-miR-
196a was found to be significantly decreased in SSc patients (100). 
Hair miR-29a was obtained from 20 SSc patients, 5 dermatomyosi-
tis, and 13 controls to determine its usefulness as a biomarker. Hair 
miR-29a was significantly lower in SSc patients, and the decreased 
levels were associated with a higher prevalence of phalangeal 
contractures (98). We may see more studies using hair miRNAs 
to assess biomarkers and disease phenotypes.
immune System in SSc Pathogenesis
Role of innate immune System
Engagement of the innate immune system depends on 13 differ-
ent TLRs, which are not antigen-specific but instead recognize 
patterns and which segregate on the basis of the nature of the 
ligands they encounter such as distinct molecular patterns in 
particular pathogens, in endogenous cellular constituents, or in 
cellular products of the host [reviewed in Ref. (155)]. Considerable 
evidence suggests that TLR2 and TLR4 expressed on cells and IC 
TLR3, 7, 8, and 9 have particular relevance to SSc pathogenesis. 
For example, a rare functional polymorphism (Pro631 His) in TLR2 
(which has bacterial peptidoglycan, lipoprotein, and lipoteichoic 
acid and yeast-derived zymosan as natural ligands) is associated 
with ATA positivity and enhanced IL-6 production by dendritic 
cells when engaged by a TLR2 ligand (90, 155). TLR4 endogenous 
ligands [including fibronectin, hyaluronan fragments, heat-shock 
protein (HSP) 70, HSP9, high-mobility group box-1 (HMGB-1), 
and S100A proteins] could engage TLR4 (which is increased in SSc 
skin and lungs) and synergize with TGF-β to increase fibroblast CI 
production (155–160). Importantly, HSP70, HMGB-1, and hya-
luronan are elevated in SSc sera or tissues (161–163). Of interest, 
elevated HMGB-1 and soluble advanced glycation end products 
(sRAGE) levels in sera of patients with SSc correlated with more 
internal organ involvement, immunological abnormalities, and 
total MRSS but correlated negatively with lung function (161). 
Double-stranded RNA is recognized by TLR3, single-stranded 
RNA, and imidazoquinoline compounds by TLR7 and TLR8, 
whereas unmethylated CpG oligonucleotide sequences are rec-
ognized by TLR9 and some of these ligands are present in SSc 
(164, 165).
Siglec-1 (CD169, sialoadhesin) is a marker for macrophage 
activation and its expression was found to be increased CD14+ 
monocytes in peripheral blood and on macrophages in dermis of 
lesional skin of a subset of patients with SSc (125). Furthermore, 
Siglec-1 was induced in peripheral blood CD14+ monocytes from 
normal donors when cultured with IFNα, TLR3, 7, or 9 agonists but 
not by TLR2 or 4 (125). In the skin, activated macrophages express-
ing Siglec-1 may also release cytokines or growth factors that are 
able to stimulate fibroblasts or myofibroblasts to synthesize CIs 
and other matrix components (125). In addition, sera containing 
autoantibodies from patients with SSc induce high levels of IFNα 
in normal monocytes that is inhibited by pretreatment of the sera 
with bafilomycin and RNA-degrading enzymes, suggesting that 
the immune complexes in SSc sera contain RNA that can bind IC 
TLRs (166). While other agents (e.g., IL-4, LSP, IFNβ, IFNγ) might 
also induce Siglec-1 expression on monocytes/macrophages in SSc, 
these findings are compatible with the notion that generations of 
IFNα by activation of IC TLRs 3, 7, or 9 agonists might be ongoing 
in a subset of SSc patients (125, 167).
interferon Signature in SSc
Interferons are multifunctional cytokines that are responsible for 
inducing cellular resistance to viruses. IFN-α, -β, and -ω are type 
1-IFNs. There is evidence for a prominent IFN signature in SSc. 
For example, peripheral whole blood cells in 50% of SSc patients 
have increased expression of IFN-regulated genes and lung tissues 
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from SSc patients with ILD have increased IFN and IFN-regulated 
gene expression (168, 169). It appears that the IFN signature in SSc 
discussed below may arise from activation of TLRs expressed on 
the surface of cells by infectious agents or by endogenous proteins, 
RNA, DNA, and other cellular products that can trigger IC TLRs 
summarized above. IFN regulatory factors (IRF) coordinate the 
expression of IFN and IFN-inducible genes that help regulate the 
innate and adaptive immune responses (169, 170). Thus far, IRF5, 
IRF7, and IRF8 appear to be relevant to SSc (169) (see Table 3).
iRFSNP Associations
IFN regulatory factor 5, a major regulator of type 1-IFN, induces 
the transcription of IFN-α and other pro-inflammatory cytokines, 
is involved in TLR signaling, and is critical for activation of IFN-
associated genes (109, 169) (see Table 3). IRF5 has association 
with SLE (171–173), and multiple studies have shown SNPs of 
IRF5 are associated with SSc susceptibility. IRF5 rs2004640*TT was 
found to have a strong association with dcSSc, fibrosing alveolitis, 
antinuclear antibody (ANA), and ATA positivity in a French 
cohort (38). In addition to rs2004640, these same authors found 
an association between rs3757385 and rs10954213 variants and SSc 
(43). In this study, IRF5 haplotype “R” was identified as a risk while 
haplotype “P” was protective (43). A Japanese case–control associa-
tion study with 281 SSc and 477 controls found that rs2004640, 
rs10954213, and rs2280714 were all significantly associated with 
SSc, with rs2280714 having the strongest association with SSc, 
and these SNPs were significantly enriched in dcSSc and ATA-
positive patients (45). Carmona et al. found that SNPs rs10488631, 
rs2004640, and rs4728142 showed strong associations in SSc global 
disease, and that association of rs20004640 was dependent on 
rs4728142 (174). rs728142*A-rs2004640*T haplotype explained 
this association suggesting that all three haplotypes provide an 
additive effect (174). In another study, IRF5 SNP rs4728142 was 
found to be predictive of longer survival in SSc patients with 
ILD (41). IRF7 is upregulated in peripheral blood cells from 
patients with early SSc and is associated with ACA-positive SSc 
(175). IRF8 is induced by IFNγ and modulates TLR signaling 
(24). Polymorphism rs11642873 in the IRF8 gene was found to 
be associated with lcSSc (24). IRF8 SNP rs2280381 was found to 
have association with SSc in a Japanese population consisting of 
415 SSc and 16,891 controls with a replication study consisting 
of 315 SSc (68). While associations of the above variations in IRF 
genes with certain manifestations do not establish cause and effect, 
they suggest genes that regulate IFN expression and downstream 
effects may play a central role in determining disease severity and 
specific organ involvement.
inflammasome and SSc
The cytoplasm of cells also contains another pattern recogni-
tion receptor (PRR) system called the nucleotide-binding and 
oligomerization domain (NOD)-like receptor (NLR) family that 
recognize IC motifs and, when activated via the “inflammasome” 
involves NFκB and mitogen-activated protein kinase (MAPK), 
which in turn stimulates production of pro-inflammatory 
cytokines IL-1B and IL-18. Polymorphisms of one of the NOD 
family members, NLRP1, are associated with ILD and ATA positiv-
ity in patients with SSc (176). Relevance of the NOD family to SSc 
was further evidenced by studies showing inhibition of inflamma-
tory activation-reduced IL-1β and CI production by SSc lesional 
fibroblasts and studies in NALP3 null mice showing they were 
resistant to lung fibrosis (177, 178). NLRP3 and pro-inflammatory 
cytokines (IL-1β and IL-18) were found to be increased in skin 
biopsies of patients with dcSSc or lcSSc compared to age-matched 
control and correlated with MRSS (179).
Transitioning from innate to Adaptive immunity
Rather than two separate and mutually exclusive immune systems, 
it is being realized that there is likely an ongoing interplay between 
the innate and adaptive immune systems (180). Attention has 
focused on innate lymphoid cells (ILCs) that are involved not 
only in immediate immune host defense but also in maintaining 
homeostasis of mucosal and lymphoid tissue (180, 181). Three 
different types of ILCs have been described to-date: ILC1, ILC2, 
and ILC3 (181). These ILCs do not express somatically rear-
ranged antigen receptors, but express MHC Class-II and possess 
transcription factors and cytokine profiles reminiscent of Th cells 
(181, 182). ILC1s, like Th1 cells, utilize T-bet and produce IFNγ; 
ILC2s, like Th2 cells, utilize GATA-binding protein-3 (GATA-3) 
and produce IL-5, IL-9, and IL-13; and ILC3s, like Th17 cells, 
utilize RAR-related orphan nuclear receptor gamma transcription 
factor (RORγt) and produce IL-17A and IL-22 (181). ILCs express 
TLRs and IL-1 receptor, and ILC2s and ILC3s can act as APC 
similar to dendritic cells (181, 183, 184). In mouse models, ILC3s 
were shown to promote antigen-specific CD4+T cells and antigen-
specific T-cell-dependent B-cell antibody production (181). What 
role ILCs play in innate and adaptive immunity in SSc remains to 
be defined and ongoing research should eventually better elucidate 
how ILC effect transition from innate to adaptive immunity.
Dendritic cells by using surfaces and IC PRRs play key roles in 
linking innate immune response to adaptive immune responses 
by identifying antigens from pathogen-associated or damage-
associated molecular patterns (PAMPS or DAMPS) by using TLRs, 
NLRs, RIG-I-like receptors (RLRs), and receptors for advanced 
glycation end products (RAGE) (185). The identified antigens are 
then processed and the information is presented to T cells in the 
context of MHC-II/antigen complex binding the T-cell receptor, 
CD86/CD80 costimulation of T-cell CD28, followed by release of 
cytokines from dendritic cells that affect T-cell differentiation and 
effect Th1, Th2, Th17, and T regulatory (Treg) cell differentiation 
(185, 186).
Adaptive immunity in SSc
A number of observations over several decades strongly implicate 
a major role for the adaptive immune system in SSc pathogenesis. 
These include the development of features of SSc in chronic graft-
versus-host disease (cGVHD) in humans, which is largely medi-
ated by donor T cells and reversal of fibrosis and vasculopathy after 
autologous hematopoietic CD34+ stem cell treatment of patients 
with SSc (187, 188).
Immunohistochemical analysis of skin of patients with 
SSc shows perivascular and tissue accumulations of activated 
CD4+ T cells, monocytes, and CD4+CD8+ double positive T cells 
that express high levels of IL-4 (189, 190). DNAX accessory 
molecule-1 (DNAM-1) modulates adhesion; co-stimulates 
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T lymphocytes; expresses on most CD4+ and CD8+ T cells, NK 
cells, monocytes, platelets, and some B cells; and is found to be 
expressed on inflammatory cells in biopsies of lesional skin of 
patients with SSc (191).
Autoantigens Recognized by SSc T Cells
Of particular significance is the finding in lesional SSc skin sites of 
Vdelta1+/gamma/delta T cells that express HLA-DR and CD49d, 
suggesting that they have homed to these locations and expanded 
(192). Furthermore, analysis of T-cell repertoire in different skin 
locations from the same patient is compatible with clonal expan-
sion of T cells to a widely distributed and persistent antigen (193). 
A variety of autoantigens that elicit T-cell responses in patients 
with SSc are widely distributed in tissues, have been described, and 
include types I, II, and V CIs (CI, CII, CV); laminin; low molecular 
weight (MW) N-sulfated heparin sulfate; 3500 MW RNA antigen; 
elastin; and DNA topoisomerase I (189, 194–198). Of potential 
relevance is the finding that the CI-specific CD25+CD4+ T cells 
isolated from SSc PBMC have a memory (CD45R+) phenotype 
(195). Most patients with SSc have production of IFNγ by their 
PBMCs when cultured with CI or constituent α1 and α2 chains, 
which can be reduced by inducing immune tolerance via chronic 
administration in a dose-dependent manner by oral bovine CI 
(199, 200). In a double-blind, randomized clinical trial of daily oral 
bovine CI or placebo for 12 months, patients with dcSSc ≥3 years 
duration, patients receiving oral bovine CI had a significant 
improvement in MRSS compared to the placebo-treated patients 
(201). These studies suggest CI might be a widely distributed 
relevant antigen in SSc.
Microchimerism in SSc
Fetal–maternal and maternal–fetal microchimerisms have been 
proposed as mechanisms triggering autoimmunity in SSc and 
other autoimmune diseases (202–204). This microchimerism, in 
susceptible individuals, could initiate a type of cGVHD producing 
SSc with the microchimeric cells acting as effectors or as targets 
of an immune response (204). It is noteworthy that, in women 
with SSc who have given birth to male children, male offspring 
Th2-oriented T cells that express high levels of IL-4 are found in 
these women’s skin and blood (205).
CD4+ Regulatory T Cells and CD4+ Th17  
T Cells in SSc
The dysregulation in SSc of Th17 and/or Tregs (mostly 
CD4+CD25+Foxp3+) has been reported by several groups. 
Different (and contradictory) results have been reported that seem 
to be dependent to some extent on how Tregs are defined by flow 
cytometry. Tregs have been found to be increased in the blood of 
SSc patients but have defective suppressive function (206). Papp 
et al. (207) reported decreased percentages and suppressive func-
tion of CD4+CD25+Tregs but increased percentage of Th17 cells in 
blood of SSc patients (207). Klein et al. (208) reported SSc patients 
had elevated CD4+D24+Foxp3+Tregs in lesional skin but normal 
percentages in the peripheral blood (208). Slobodin et al. reported 
an increased number of Tregs in the blood of SSc patients but no 
concomitant increase in TGF-β or IL-10 production by CD4+T cells 
(209). Fenoglio et al. found SSc patients had reduced frequency in 
blood and reduced suppressive function of CD4+CD25+Tregs and 
increased Th17 cell expansion after polyclonal or antigen-specific 
stimulation of SSc PBMC (210). Finally, Mathian et al. analyzed 
circulating activated (a)Tregs (CD4+CD45RA(CD25bright T cells) 
and resting (r)Tregs (CD4+CD45RA+CD25+ T cells) in controls 
and SSc and found decreased frequency but normal suppressive 
function of both types of Tregs and in the lesional skin found no 
CD4+Foxp3 mRNA in SSc compared to normal donor skin (211).
Abnormalities in Treg numbers or function could facilitate 
development of adaptive immune responses to autoantigens in 
SSc. Mast cells and S1P which are increased in SSc are two potential 
antagonists for proper development and function of Treg cells, as 
both have the capacity to inhibit Tregs (212–214). Furthermore, 
both S1P and mast cells enhance generation of Th17 cells (213, 
215). The field of Tregs is still evolving and future studies with 
better markers for Treg subsets will need to be performed to better 
characterize this role in SSc.
Possible influence of vitamin D Deficiency and 
Lysophospholipids on immune Dysregulation  
in SSc
Vitamin D insufficiency/deficiency has been implicated in trigger-
ing and enhancing a number of autoimmune diseases. Low serum 
25(OH)D concentrations have been reported to be more common 
in patients with SSc than in healthy controls. Furthermore, 25(OH)
D levels have been reported to negatively correlate with several 
laboratory and clinical parameters in European Disease Activity 
Score, Raynaud’s phenomenon (RP), erythrocyte sedimentation 
rate, systolic pulmonary artery pressure, MRSS, and positively 
correlate with carbon monoxide diffusion lung capacity (216–218). 
A number of effects of 1,25(OH)2D3 on immune cells have been 
reported that could explain its ability to decrease autoimmunity 
and, conversely, how VitD deficiency contributes to increased 
autoimmunity [these are summarized in Ref. (219)]. For example, 
effects of 1,25(OH)2D3 on APC include: (1) downregulation of 
MHC class-II molecule expression in APC; (2) downregulation of 
surface expression of co-stimulatory receptors (CD40, CD80, and 
CD86) and other maturation-induced proteins (CD1a, CD83); (3) 
inhibition of dendritic cell maturation, induction of tolerogenic 
DC that are able to induce Treg cells; (4) inhibition of IL-12 p70 
release from DC; and (5) inhibition of pro-inflammatory cytokines 
in monocytes and macrophages (219). Effects of 1,25(OH)2D3 on T 
cells include: (1) inhibition of antigen-specific and lectin-stimulated 
T-cell activation and progression from G1a to G1b proliferation; 
(2) inhibition of IL-12, IFNγ, IL-2 release; (3) stimulation of IL-4, 
IL-5, and IL-10 production; and (4) inhibition of Fas ligand (FasL) 
expression by activated T cells (219). The effect of 1,25(OH)2D3 
on B cells is to inhibit production of IgA, IgE, IgG, and IgM and 
in NK cells to inhibit IFNγ production (219, 220).
Administration of VitD3 in escalating daily doses of 2000 U 
(2000 U for the first month, then 4000 U for the second month, 
and 8000  U for the third month) to healthy VitD-deficient 
individuals induced increased frequencies of CD38+ B cells and 
reduced frequencies of CD4+IFNγ+ and CD4+IL-17+ T-helper 
cells (221). Treatment of SLE patients with hypovitaminosis D 
with 100,000 U of VitD3 weekly for 4 weeks and then monthly 
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for 6 months resulted in an increase in naïve CD4+ T cells and 
CD3+CD4+CD25hiCD127–Foxp3+Tregs and decreases in CD19+ B 
cells, anti-ds DNA antibody titers, and proteinuria (222). Similar 
studies with high-dose VitD supplementation have not been 
reported in patients with SSc, but the above studies in SLE and 
normal hypovitaminosis individuals demonstrate the potential 
for immune modulation by high-dose VitD supplementation that 
might decrease autoimmunity in patients with SSc.
Lysophosphatidic acid and S1P levels are increased in sera of 
patients with SSc, suggesting they may play a role in different 
aspects of the disease (214) [reviewed in Ref. (223)]. Platelets, 
macrophages, dendritic cells, mast cells, and endothelial cells are 
sources of LPA and S1P, and these cells (plus T cells and B cells), 
NK cells, fibroblasts, and other cells express various types of LPA 
and S1P G-protein-coupled receptors (GPCRs) [reviewed in Ref. 
(223)]. PPARγ, which resides intracellularly and counters TGF-β 
fibrogenesis, is also an additional receptor for LPA (224). In addi-
tion to S1P being able to “disarm” Foxp3 Tregs mentioned above, 
S1P and LPA regulate the function, migration, and trafficking of all 
lymphoid cells and monocyte/macrophage/dendritic cells with S1P 
also being able to sequester T cells in the thymus and peripheral 
lymphoid organs, resulting in some instances in lymphopenia, 
which is frequently found in patients with SSc (225–227). By acting 
on APC, S1P and LPA each can suppress development of Th1 
T-helper cells, but they have different effects on Th2 T-helper cells 
in that S1P suppresses their development while LPA fosters their 
development (228). Th2 T-helper cell predominance is a feature of 
some patients with SSc with production of IL-4 and IL-13, which 
facilitate development and expansion of B cells and autoantibodies 
that are common features of SSc. Lysophospholipids need further 
study in SSc, given the potential to regulate immunity.
vascular Abnormalities in SSc
Vascular dysfunctions and abnormalities leading to RP, digital 
ulcers, and nail-fold capillary abnormalities usually are among 
the earliest and key manifestations of SSc. The various vascular 
abnormalities are summarized in Table  5. Postmortem exami-
nation reveals the vascular changes in SSc are more typical of a 
vasculopathy than of a vasculitic process – given the paucity of 
inflammation in the vessel wall with widespread systemic intimal 
proliferation in the pulmonary, coronary, and the renal arteries 
(229). Patients with SSc who develop PAH and renal crisis exhibit 
vascular lesions characterized by classic concentric intimal prolif-
eration, marked luminal obstruction, lymphocyte infiltration, and 
relative paucity of plexiform lesions (230–233).
Earliest signs of vascular dysfunction include impaired vas-
cular tone and vascular permeability (234). Impaired balance of 
vasoconstrictor substances (e.g., ET) and vasodilator substances 
(e.g., NO), plays important roles in vascular dysfunction. Platelet 
activation and enhanced coagulation with reduced fibrinolysis also 
contribute to the vasculopathy in SSc. Abnormalities in the vascular 
system can be seen in clinically normal skin of SSc patients (235). 
Large gaps between endothelial cells, vacuolization of endothelial 
cell cytoplasm, and loss of membrane-bound storage vesicles are 
some of the earliest detectable changes in the endothelial cells 
(235–237). In a 20-year follow-up study, sequential changes can be 
seen in capillaries (4) in skin, which include capillary enlargement, 
capillary loss, and telangiectasia. Further morphologic changes in 
vessel wall occur including fibrosis. Such capillary changes are wide 
spread in internal organs (e.g., lungs, heart, kidneys, and muscles) 
(238). Intimal proliferation and accumulation of proteoglycans in 
the arterioles and small arteries are also common (239, 240). The 
operative mechanisms that lead to this widespread vasculopathy 
in SSc of unknown, but animal models and in vitro studies have 
provided some clues.
Mechanism of vascular and endothelial Cell 
injury in SSc
The etiology of the initial vascular damage in SSc is not known 
and is a topic of speculation. Infectious agents, cytotoxic T cells, 
NO-related free radicals, and autoantibodies against endothelial 
cells have all been implicated (234). Endothelial cell dysfunction, 
neural abnormalities, and various other intravascular defects likely 
contribute to the impaired vascular flow (241).
Endothelial Cell Injury
Evidence suggests that endothelial cell injury is an early and 
central event in the pathogenesis of SSc vasculopathy, and viral 
agents [especially human cytomegalovirus (hCMV)], cytotoxic 
T cells, antibody-dependent cellular cytotoxicity (ADCC), anti-
endothelial cell antibodies, and ischemia-reperfusion injury are 
all suggested mechanisms for endothelial cell damage (234, 242). 
Levels of antibodies to hCMV are increased in patients with SSc 
which is reminiscent of the association of hCMV antibodies with 
vascular intimal proliferation and vasculopathy in patients with 
graft rejection and coronary artery bypass restenosis (243). In addi-
tion, there is evidence of binding of some ATAs to an epitope in 
hCMV-derived UL94 protein which happens to also show homol-
ogy to MVEC surface protein tetraspan novel antigen-2 (NAG-2) 
(243). Apoptosis of MVEC can be effected by purified anti-UL94 
peptide antibodies (244). Cytotoxic CD4+ T cells induce MVEC 
apoptosis via in  vitro Fas-related pathway in contrast to CD8+ 
TABLe 5 | Key vascular abnormalities of SSc.
Presence of proliferative vasculopathy with intimal proliferation in peripheral, 
pulmonary, coronary, and renal arteries in the absence of inflammation is a 
hallmark feature of scleroderma
Endothelial cell damage is a key and early process. It precedes fibrosis and 
particularly involves the arterioles
Early detectable changes in the endothelial cells include disappearance of 
membrane-bound vesicles, vacuolization of endothelial cell cytoplasm, and 
gaps between endothelial cells
Defective angiogenesis is an early event in the form of drop out of capillaries 
and abnormal capillary architecture without a compensatory process
There are conflicting reports regarding the presence and role of circulating 
endothelial progenitor cells in SSc
There is dysregulation of coagulation and fibrinolysis process
Platelets show enhanced aggregability to various triggers such as type I 
collagen and adenosine etc…, and are activated throughout the clinical course 
of SSc
LPA and S1P could potentially contribute to the vasculopathy via endothelial 
cell activation, neointimal formation, vascular leakiness, increased 
vasoconstriction, cardiac fibrosis, and hypertension
June 2015 | Volume 6 | Article 27219
Pattanaik et al. Pathogenesis of SSc
Frontiers in Immunology | www.frontiersin.org
T cells, NK, and LAK cells which utilize the granzyme/perforin 
system (243). ADCC to MVEC is operative in many patients 
with SSc (243). Anti-endothelial cell antibodies are commonly 
found in sera from patients with SSc and are capable of inducing 
MVEC apoptosis directly in vitro (245). Ischemia and reperfusion 
injury (especially associated with attacks of RP) is accompanied 
by upregulation of expression of junctional adhesion molecules 
(JAMs). This upregulation indicates endothelial dysfunction and 
allows attachment of platelets and neutrophils to the endothelium 
that is thought to lead to MVEC injury through production of 
superoxide radicals (which limit release of vasodilation substances 
such as NO and prostacyclin) (243, 246, 247). The major evidence 
for the presence of the endothelial injury in SSc is high serum 
levels of circulating von Willebrand (VW) factor, ET-1, increased 
levels of circulating viable and dead endothelial cells, and soluble 
JAM-A and JAM-C (234, 247–251). Subendothelial tissue forms 
a nidus for platelets to aggregate and initiates fibrin deposition 
and intravascular thrombus formation (1). The role of endothelial 
apoptosis is not clear. Sgonc et al. (252) demonstrated endothelial 
cell apoptosis in the University of California at Davis chicken lines 
200/206, which spontaneously develop an SSc-like disease (252). 
Apoptotic endothelial cells may contribute to tissue injury when 
engulfed by immature dendritic cells and macrophages, which 
subsequently present cellular antigens to CD8+ T cells, causing fur-
ther tissue injury (253). These apoptotic endothelial cells can also 
activate the alternate complement pathway and coagulant pathway 
leading to vasculopathy (254, 255). Proof that there is ongoing 
endothelial apoptosis in SSc is thus far lacking, and Fleming and 
Wanless (256) failed to detect apoptotic endothelial cells in their 
study, although they did demonstrate loss of VE-cadherin, which 
regulates endothelial barrier function and found evidence of IFNα 
signaling (256). IFNα signaling suggests endoplasmic reticulum 
stress and the unfolded protein response in these cells (257, 258).
Defective Angiogenesis
The remarkable loss of capillaries and small vessels in patients 
with SSc suggests a defect in the process of angiogenesis. Tissue 
ischemia usually leads to the expression of angiogenic growth 
factors [e.g., vascular endothelial growth factor (VEGF)], which 
causes vasodilatation, proliferation, and migration of endothelial 
cells and stabilization of the lumina to form new vessels (259). 
Plasma levels of VEGF are elevated in SSc, and this could stimulate 
angiogenesis (260). Levels of other proangiogenic factors [e.g., 
PDGF, placental growth factor (PGF), and fibroblast growth factor 
2 (FGF-2)] are also considerably elevated in the plasma of SSc 
patients (261). Expression of VEGF and its receptors, VEGFR1 
and VEGFR2, are increased in skin of SSc patients (260, 262, 
263). In addition to elevated level of VEGF, other proangiogenic 
mediators (such as ET-1, adhesion molecules, and chemokines) 
are found in the circulation of SSc patients (264). Elevated levels 
of antiangiogenic factors such as angiostatin, platelet factor-4 (also 
called CXCL4), thrombospondin-1 (TSP-1), and IL-4 have been 
described in patients with SSc (264, 265).
Defective Vasculogenesis
The role of vasculogenesis in SSc is not clear, and there are 
conflicting reports regarding the presence and role of circulating 
endothelial progenitor cells in SSc (266). Increased levels of circu-
lating endothelial progenitor cells have been demonstrated which 
supports their mobilization from bone marrow (267). However, in 
another study, there were substantially reduced numbers of bone 
marrow-derived circulating endothelial precursors compared to 
healthy subjects or patients with RA. The lowest number of these 
cells was observed in SSc patients with active fingertip ulcers, and 
this may suggest inadequate recruitment of these precursor cells 
and impaired vascular repair mechanisms (268). Atorvastatin 
can be effective in RP – perhaps by increasing the number of 
circulating endothelial progenitor cells, which suggests a role 
of endothelial progenitor cells in vascular dysfunction (269). 
Apoptosis of endothelial progenitor cells by a circulating factor 
has been implicated as the potential mechanism for the reduced 
number of circulating precursor cells in SSc (270). Mesenchymal 
stem cells might be another source of endothelial progenitor cells. 
In SSc, the angiogenic potential of these cells is reduced (271). This 
suggests that endothelial repair may be affected by unknown SSc 
disease effects on the bone marrow.
Pericytes mediate vascular maturation and stabilization 
during angiogenesis (272). They can further differentiate into 
vascular smooth muscle cells, fibroblasts, and myofibroblasts 
(273–275). Pericytes express PDGFR-β, and high molecular weight 
melanoma-associated antigen (HMW-MAA) in vascular lesions in 
SSc patients with associated RP and ANA (276). Another marker 
of angiogenic pericytes is regulator of G protein signaling (RGS-5), 
which is highly expressed in SSc vasculature (277). The exact role of 
RGS-5 is not clear, but it can negatively regulate vessel maturation 
(278). Pericytes proliferate and contribute to increased vascular 
wall thickness, which is characteristic of SSc vasculopathy (279).
Endothelial to Mesenchymal Cell Transition in the 
Pathogenesis of SSc Vasculopathy
There is subendothelial accumulation of activated fibroblasts or 
myofibroblasts and production of excessive CI and ECM com-
ponents in blood vessels of SSc patients (1). During this process, 
endothelial cells lose their specific markers such as VE-cadherin 
and VW factor and acquire a mesenchymal phenotype expressing 
α smooth muscle actin (αSMA), Vimentin, and CI. It is postulated 
that endothelial cells might transform into mesenchymal cells 
induced by local growth factors and cytokines (1). The exact 
molecular mechanism and the cytokines involved are not known, 
but TGF-β has been implicated. There are recent reports of TGF-β 
being involved in various disease processes such as endothelial 
to mesenchymal transformation (280–284). Li and Jimenez (285) 
further examined the role of TGF-β in the transformation process 
and the signaling pathways involved (285) in a murine pulmonary 
endothelial cell model. They concluded that TGF-β could lead to 
mesenchymal transformation of the endothelial cells. They further 
demonstrated that the transformation is associated with strong 
upregulation of transcriptional repressor snail-1 and is mediated 
by the c-abl kinase and protein kinase C-δ. Snail-1 is a zinc-finger 
transcription factor that forms a complex with Smad3/Smad4 (1). 
Snail-1 induces numerous transcriptional events that could lead 
to expression of a mesenchymal phenotype. Besides this, Wnt 
signaling as well as NOTCH signaling pathways might be involved 
in this endothelial–mesenchymal transformation process (1). 
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Other potential mediators of this transformative process include 
PDGF (286), VEGF (287), insulin-derived growth factor (288), 
CTGF (289), ET-1 (290), and miRNAs (291, 292). Endothelial 
to mesenchymal cell transition is an interesting concept but 
needs further study to determine what role, if any, it plays in SSc 
vasculopathy.
Circulating Mediators of Vasculopathy
Higher levels of ET-1 have been observed in patients with scle-
roderma renal crisis, lung fibrosis, PAH, and RP (293). Increased 
ET-1 expression is associated with increased ET-1B receptor in 
the skin and lung tissue of SSc patients (294).
In SSc, there is a reduction in eNOS gene expression and NO 
release in SSc and MVEC derived from lesional and non-lesional 
skin biopsies in the steady-state and after shear stress (295). This 
is probably associated with deficient endothelium-dependent 
relaxation in SSc (296). Impaired NO results in alteration of 
vascular tone, enhancement of platelet aggregation, and increased 
susceptibility of endothelial cells to oxidative injury. NO also limits 
cytokine-induced endothelial cell activation and monocyte adhe-
sion and inhibits the endothelial cell release of IL-6 and IL-8, which 
are important inflammatory cytokines (297). Further, NO inhibits 
vascular smooth muscle cell proliferation through elevation of 
cyclic GMP and inhibition of mitogenic proteins, TGF-β and 
PDGF. Therefore, impaired NO production in SSc may contribute 
to the pathogenesis of arteriolar intimal proliferation and may have 
a prominent role in pathophysiology of the disease.
Coagulopathy in Systemic Sclerosis
Coagulation and fibrinolysis processes are dysregulated as evidenced 
by presence of microvascular thrombosis and enhanced fibrin 
deposition frequently seen in the vasculature of SSc patients. The 
loss of balance between fibrinolysis and coagulation contributes 
to vessel engulfment with fibrin and breakdown of vessel patency 
(298). The authors demonstrated impairment of fibrinolysis and 
activation of the coagulation pathway in a study of 29 patients 
(298). Activation of the coagulation system, as well as elevated 
levels of fibrinogen and VW factor, has been demonstrated in 
patients with SSc (299–302). Reduction of fibrinolysis, expressed 
as defective tissue t plasminogen activator (tPA) antigen release 
and/or elevated tPA inhibitor (PAI) antigen, supports existence of 
heterogeneous hypofibrinolytic pattern in SSc (303).
Plasmin has both pro-fibrotic and anti-fibrotic properties [pro-
fibrotic by activating TGF-β and anti-fibrotic by activating both 
hepatocyte growth factor (HGF) and MMPs] (304, 305). Plasmin 
is inactivated via formation of a complex with α2-antiplasmin 
(α2AP), and elevated levels of plasmin-α2AP are associated with 
several fibrotic conditions including SSc (306). α2AP promotes 
fibrosis by activating phospholipase A2 by binding to adipose 
triglyceride lipase (ATGL) to generate PGF2α, which in turn 
stimulates production of TGF-β (307). Levels of α2AP are elevated 
in lesional BLM skin in mice, which is induced by CTGF via extra-
cellular signal-regulated kinase 1/2 (ERK 1/2) and JNK pathways 
(308). α2AP induces αSMA+ myofibroblasts in vitro and mice with 
deletion of α zinc-finger alpha protein gene (αZAP) exhibit less 
infiltration of myofibroblasts at the site of BLM injections in the 
skin (308). Plasmin increases ECM degradation, and inhibition 
of plasmin of α2AP decreases ECM degradation, which could be 
another mechanism by which α2AP could promote fibrosis.
Platelet Abnormalities in SSc
Chronic activation of platelets and their released products could 
contribute to the vascular, immunologic, and connective tissue 
pathology of SSc (309). SSc platelets show enhanced aggregation 
to various triggers [e.g., CI, adenosine diphosphates, 5-hydroxy-
tryptamine (309–311), ET-1, S1P, and LPA (223)]. ET-1 and S1P 
cause vasoconstriction by engaging S1P2 and S1P3 receptors (312). 
In the human fetal lung fibroblast line (FH-1), S1P utilizes S1P1 
receptors to inhibit TGF-β1-induced αSMA expression while 
utilizing S1P3 receptors to stimulate αSMA expression (313). Sera 
from patients with SSc have elevated levels of arachidonoyl-LPA 
and S1P (214). LPA induces platelet aggregation, vascular smooth 
muscle proliferation, and neointima formation, which can induce 
vasospasm and RP (314–317).
The various platelet-derived factors include: inflammatory 
mediators [NO, serotonin, thromboxane A2, prostaglandin (PG)
D2, PGE2, PGF2, 12-hydroxyeicosatetraeonic acid, β thrombo-
globulin, neutrophil-activating peptide-2, platelet factor-4, platelet 
activating factor, adenosine, histamine, P-selectin, CD40 ligand 
(CD40L), dinucleoside polyphosphates, 2-arachidonyl glyceride, 
MMP-27], chemokines [macrophage inflammatory protein (MIP-
1α); monocyte chemoattractant protein-3 (MCP-3); IL-8; and 
regulated upon activation, normal T-cell expressed and secreted 
(RANTES)], cytokines [IL-1β and granulocyte monocyte-colony 
stimulating factor (GMCSF)], and growth factors [(PDGF) A, B, 
C, D, TGF-β1 and 2, epidermal growth factor, VEGF-A and C, 
brain-derived neurotrophic factor, insulin-like growth factor-1 
(IGF-1), basic fibroblasts growth factor (bFGF), HGF, and CTGF] 
(309). Platelets from scleroderma patients overexpress a specific 
non-integrin 65-kDa receptor for CI, phosphatidylinositol (PI)-3 
secondary to increased nitrotyrosylation and increased protein 
kinase B (Akt) activity (309, 318). Overexpression of these media-
tors is induced by cytokines produced by T cells and monocytes 
activated by autoantigen such as CI that (in turn) changes the 
phenotype of megakaryocytes (318). The platelets store numerous 
fibrogenic mediators and contribute to chronic tissue fibrosis in SSc 
by release into tissue of TGF-β1, TGF-β2, PDGF-A, B, C, D, LPA, 
S1P, adenosine, bFGF, CTGF, and IGF-1. These aforementioned 
mediators have many biological properties and effects on a host 
of cells that could also facilitate and contribute to autoimmunity 
and fibrosis (5).
Animal Models Resembling SSc Vasculopathy
Animal studies in mice recapitulate some of the vasculopathy of 
SSc. Mice with a conditional deletion of Fli1 develop systemic 
vascular lesions characterized by capillary dilation, vascular 
fragility, stenosis of arterioles, increased vascular permeability, 
micro-aneurysms, decreased expression of platelet/endothelial cell 
adhesion molecule (PECAM)-1, PDGF-β, and S1P type I receptor 
(S1P1) and increased endothelial cell MMP-9 expression (319).
Caveolin-1 (cav-1) is one of three membrane proteins that coat 
caveolae which are plasma membrane invaginations important 
in clustering together of receptors that can influence signal 
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transmission of the specific receptor ligand (320). Cav-1 is involved 
in internalization and degradation of TGF-β receptors, thereby 
reducing signaling by TGF-β (321, 322). There is decreased expres-
sion of cav-1 in lesional skin and lungs of patients with SSc and in 
lungs of patients with idiopathic pulmonary fibrosis (IPF) (323, 
324). Cav-1 null mice develop PAH and right and left ventricular 
enlargement and failure (325). However, in contrast to cav-1 null 
mice with PAH, in human IPAH, there is an apparent increase in 
cav-1 expression in the PASMC compared to healthy controls and 
that the over expression of cav-1 increases capacitive Ca++ entry and 
DNA synthesis in PASMC (326). The cav-1 null mice also develop 
pulmonary fibrosis, raising questions regarding the etiology of the 
PAH in this model which is yet to be clearly defined. In a French 
and Italian SSc population, Cav-1 rs959173C showed protective 
association with SSc and lcSSc (327). The rs959173C protective 
allele is associated with increased CAV-1 protein expression (327).
Fos-related antigen-2 (Fra-2) transgenic (TG) mice develop 
microvascular and proliferative vasculopathy and express Fra-2 
in vascular structures (endothelial cells and vascular smooth 
muscle cells) similar to its expression in skin of SSc patients (328). 
An early event in the Fra-2 TG model is apoptosis of endothelial 
cells (328). The Fra-2 TG mice also developed pulmonary vascular 
lesions resembling SSc-associated PAH and later developed dermal 
and pulmonary fibrosis resembling the “non-specific interstitial 
pneumonia” (NSIP) (328). These results suggest Fra-2 might be 
involved in pathogenesis of SSc vasculopathy and to-date this is the 
only mouse model that manifests both vasculopathy and fibrosis 
with features shared by the human SSc disease.
Pulmonary Arterial Hypertension
Cellular Stress in SSc-PAH
Patients with lcSSc, who also have PAH, have the highest expres-
sion of the endoplasmic reticulum stress/unfolded protein 
response genes, Activating Transcription Factor-4al-b, a spliced 
form of X-box BP, and immunoglobulin-heavy-chain BP (257). 
In PBMC of the lcSSc patients, HSP gene (DNAJB1), and IFN-
regulated genes (IFIT1, IFIT2, and IFITM1) were upregulated, 
but IRF4 was downregulated compared to healthy controls (257). 
Further analysis showed that the severity of PAH (as reflected 
in pulmonary artery pressure) positively correlated with level of 
DNAJB1 expression, while endoplasmic reticulum stress marker 
correlated with IL-6 levels in the whole lcSSc population (257).
interferon Signature in SSc-PAH
Type I IFNs are implicated by the association of use of IFNα in the 
treatment of hepatitis and of IFNβ in the treatment of MS with 
development of PAH (118, 119). Diseases in which there is an “IFN 
signature” (such as SLE, SSc, and infection with HIV) are associ-
ated with development of PAH (120–124). Furthermore, IFNα and 
IFNγ (added to cultures of human PASMC primed with TNFα 
or to cultures of human lung MVEC or human lung fibroblasts) 
cause release of the potent vasoconstrictor, ET-1, and of IP-10 
(117). In a series of 128 SSc patients with PAH and 35 patients 
with no PAH, the SSc patients with PAH had higher levels of IP-10 
and ET-1 in their sera compared to SSc patients without PAH or 
compared to healthy controls; more SSc patients with PAH had 
detectable levels of IFNα and IFNγ in their sera than SSc patients 
without PAH (117). In this series of SSc patients, levels of TNFα, 
IL-12p70, IL-6, IL-1α, and IL-8 were significantly higher in sera 
in SSc patients with PAH when compared to SSc patients without 
PAH (117). Additional studies of this patient group revealed that 
serum levels of IP-10 in the SSc-PAH patients correlated with 
pulmonary vascular resistance, and levels of brain natriuretic 
peptide in serum, and serum IP-10 levels in the SSc-PAH patients 
inversely correlated with cardiac index and 6-min walks test 
(117). Sections of lung from patients with IPAH or with SSc-PAH 
expressed higher levels of IFNR1 in endothelium, smooth muscle 
layer, vascular interstitium, and in intravascular inflammatory 
cells as assessed by immunohistochemistry and Western blotting 
(117). While the above studies strongly implicated type I IFN as 
playing a pathogenic role in SSc-PAH and IPAH, further evidence 
was substantiated in the type I IFN α receptor 1 knockout mouse 
which was found to be resistant to experimental hypoxic PAH 
induction. These mice did not have elevated serum levels of ET-1 
when compared to WT control mice (117). Analysis of PBMC from 
patients with SSc revealed Siglec-1 and other IFN-regulated genes 
were overexpressed in patients with dcSSc, whereas patients with 
lcSSc with PAH overexpressed IL-13RA1, ICAM-1, CCR1, JAK2, 
and MCR1 (123, 125, 126). IL-13 was also elevated to higher levels 
in sera of patients with lcSSc with PAH, and MCR1 was induced 
on CD14+ monocytes suggesting monocytes are activated in lcSSc 
patients with PAH of an alternative (i.e., IL-4/IL-13) rather than 
classical (i.e., IFNγ/LPS) pathway (123).
Other Mediators and Gene Polymorphisms in 
SSc-PAH
Polymorphisms were described in the promoter of the NOS2 gene 
that confers susceptibility to PAH in SSc (144).
In another report, patients with lcSSc with PAH, had higher levels 
of circulating monocyte-related cytokine mediators (TNFα, IL-1β, 
IL-6, and ICAM-1) and vascular injury markers (VEGF, VCAM-1, 
and VW Factor), and their PBMCs exhibited increased expression 
of mRNA for ICAM-1, IL-1β, JAK2, IFNGR1, IL-13Rα1, tissue 
inhibitor of metalloproteinase (TIMP)-2, delta-aminolevulinate 
synthase 2 protein (ALAS2), CCR1, and AIF1akt (126).
Urokinase-type plasminogen activator receptor, CD87: (discussed 
under “Genetics of SSc”) SNP, UPAR rs344781G allele, is associated 
with SSc-related digital ulcers, pulmonary artery hypertension, 
ACA positivity, and lcSSc (91).
Sphingosine 1-phosphate and LPA may have effects on the 
vasculature in SSc that contribute to some of the abnormalities 
observed in the disease. For example, there is overexpression 
of VE-cadherin, IFNα signaling, and Rgs-5, which is associated 
with an antiangiogenic phenotype (188). Overexpression of Rgs-5 
may reduce signaling via S1P1 receptor and increase S1P signal-
ing through other S1P receptors that could reduce endothelial 
eNOS, increase vasoconstriction, increase vascular leakiness, and 
reduce angiogenesis [reviewed in Ref. (223)]. Furthermore, S1P 
may contribute to PAH by constricting pulmonary arteries while 
LPA may contribute to systemic hypertension, cardiac fibrosis, 
endothelial cell activation, and neointima formation (via PPARγ) 
[reviewed in Ref. (223)].
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Lysophosphatidic acid, S1P, and other chemoattractants 
(such as TGF-β1, TGF-β2, IL-8, MCP-3, and other mediators 
released from aggregated/activated platelets adhering to dam-
aged microvascular endothelium and diffusing into perivascular 
tissue) could establish chemotactic gradients that would promote 
outward transversal migration of monocytes, dendritic cells 
T and B lymphocytes, and NK cells resulting in perivascular 
accumulation of these cells to set the stage permitting innate 
and adaptive immune responses that lead to autoimmunity and 
fibrosis (223).
Fibrosis in SSc
Links to the innate and Adaptive immune 
Systems
Over three decades ago, it was recognized that human lymphocytes 
and monocytes (when stimulated by antigen or T-cell mitogen 
in vitro) elaborate soluble mediators (lymphokines, monokines, 
growth factors, chemokines, and cytokines) that induced fibroblast 
chemotaxis or (when added to cultures of human fibroblasts) 
induce fibroblast growth and synthesis of collagenase (MMP-1) 
and CI (329–340). These studies provided tangible evidence that 
immune cells are fully capable of modulating chemotaxis and 
growth of fibroblasts, as well as regulating synthesis of CI and 
CIII and the major CI degradative enzyme, MMP-1, by fibroblasts.
Later studies conducted with purified recombinant or natural 
cytokines, chemokines, and growth factors known to be synthe-
sized by cells of the innate and adaptive immune system have 
allowed fibroblasts specific functions to be assigned to certain 
ones. TGF-β1, which is produced by most cell types but also by 
CD4+CD25+Foxp3 Tregs, monocytes/macrophages, mast cells, and 
platelets and IL-4, which is produced by Th2 cells, and mast cells 
received early attention as being potent stimulators of CI synthesis 
and chemotaxis by fibroblasts (341–345).
Cells of the innate and adaptive immune system elaborate a 
variety of cytokines and chemokines in addition to TGF-β and 
IL-4 (such as IL-6, PDGF, IL-1, IL-13, IL-17, IL-5, MCP-1, and 
CTGF) that have been found to be increased in serum or in tis-
sues in which excess connective tissue matrix is accumulating in 
SSc. These cytokines/chemokines are at the interface between the 
immune system and fibroblasts.
Signal transducer and activator of transcription protein 4 is 
critical for T-cell signaling and differentiation (132–134). STAT4 
is involved in effecting a Th1 cytokine response by transmitting 
signals from IL-2, IL-12, and IL-23 receptors and in signaling after 
type 1 IFN engages its receptor (135, 136). The role of STAT4 in 
fibrosis was assessed in scleroderma mouse models. The deletion 
of STAT4 significantly reduced skin fibrosis in the BLM model 
but not in the Tsk-1/+ model (137). In the BLM model, it was 
noted that there were decreased numbers of inflammatory cells 
including T cells and proliferating T cells and decreased quantity 
of IL-6, IL-2, TNFα, and IFNγ in lesional skin of STAT4–/– vs. 
STAT4+/+ mice (137). In addition to having a role in SLE and RA 
susceptibility, STAT4 has been identified as a susceptibility gene 
in SSc (50) (see Table 3).
Macrophage migration inhibitory factor-173 acts upstream and 
activates innate immunity. It plays a role in sustaining cellular and 
inflammatory response. It causes fibroblasts proliferation and acts 
as an antiapoptotic (135).
Links to vascular Damage
Endothelin-1 is one of three isoforms and is synthesized by VE cells, 
fibroblasts, bone marrow mast cells, neutrophils, macrophages, and 
cardiac myocytes (140) (See discussion under “Genetics of SSc”). 
ET-1 is overexpressed in skin biopsies of patients with dcSSc (179).
Fos-related antigen-2, reviewed above, appears to have both 
vasculopathic and fibrogenic properties and may be a contributor 
to these processes in patients with SSc.
SSc Fibroblast Phenotype and Myofibroblasts
Earlier studies indicated that normal human dermal fibroblasts 
(grown for prolonged periods of time in vitro in the presence of 
culture medium supplemented with culture supernatants obtained 
by activating normal human donor peripheral blood lympho-
cytes and monocytes with T-cell mitogen in  vitro) acquired a 
“scleroderma-like phenotype” that resembled cultured lesional SSc 
skin fibroblasts at the ultrastructure level with respect to excessive 
production of glycosaminoglycans (346). A phenotypic character-
istic of cultured SSc lesional skin fibroblasts is that they produce 
reduced levels of MMP-1, an enzyme necessary for degradation 
of triple helical CI and CIII (347). Some SSc lesional fibroblasts 
regain production of MMP-1 after several subpassages, and when 
these fibroblasts lines are then cultured for 3 weeks with IL-13 or 
PDGF-BB, then cultured in plain medium before TNFα stimula-
tion, the production of MMP-1 in response to TNF-α stimulation is 
markedly reduced compared to normal donor fibroblasts similarly 
treated with IL-13 or PDGF-BB (348). These studies suggest that 
in vivo chronic exposure of SSc fibroblasts to certain cytokines, 
derived from activated lymphocytes and monocytes either in cir-
culation or from lymphocytes/monocytes infiltrating SSc lesional 
skin, can induce an SSc fibroblast phenotype that persists in the 
absence of the cytokines for some period of time. Platelets that are 
being chronically activated/aggregated in patients with SSc may 
also contribute some cytokines/growth factors (e.g., PDGF-BB) 
that could contribute to induction of the scleroderma fibroblast 
phenotype (309).
Fibroblasts cultured from lesional skin biopsies of patients with 
SSc contain increased numbers of myofibroblasts and synthesize 
increased amounts of CI and TIMP-1, in contrast to fibroblasts 
grown from non-lesional SSc skin or skin of healthy controls (349). 
This increased CI production phenotype reverts toward normal 
as the SSc lesional fibroblasts in culture are passaged, as shown 
by LeRoy (350). The myofibroblasts in SSc lesional skin contain 
αSMA and fibronectin ED-A splice variant, the latter being a 
requirement for TGF-β1 to induce myofibroblast formation (275, 
351). In normal wound healing, myofibroblasts contract the newly 
formed ECM, and their development and function are modulated 
by mechanical forces and stiffness of the ECM microenvironment 
(352). The origin of myofibroblasts in SSc lesional skin is not 
completely understood, but likely candidates include resident con-
nective tissue fibroblasts, epithelial cells, pericytes, and circulating 
fibrocytes. Myofibroblasts are induced by a number of cytokines, 
growth factors, and other agents present in SSc tissue or serum, 
including: TGF-β1, TGF-β3, IL-4, TNFα, IL-6, GMCSF, thrombin, 
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bradykinin, histamine, tryptase, oncostatin M, IL-13, PDGF-β, 
ET-1, TLR 2/1 ligands, and the lysophospholipids, S1P and LPA 
(5, 353–355).
Levels of IL-1α are elevated in sera of patients with SSc, and 
SSc monocytes produces more. IL-1 than normal monocytes when 
stimulated in vitro (356, 357). IL-1α and -β stimulate proliferation 
of human dermal fibroblasts and upregulate production of CI, 
TIMP, PGE2, MMP-1, and hyaluronan (358, 359). IL-1α and -β 
were observed to promote viability of cultured SSc lesional skin 
fibroblasts and myofibroblasts in vitro in the presence or absence of 
serum and directly induced expression of αSMA and N-cadherin 
(360). This suggests that IL-1 may contribute to the longevity of 
myofibroblasts in SSc skin.
Fibroblasts grown from SSc lesional skin biopsies constitutively 
overexpress IC IL-1α; and after stimulation in vitro with TNFα 
or IL-1β, both icIL-1α and icIL-1 receptor protein antagonist 
(icIL-1ra) are markedly upregulated compared to normal donor 
fibroblasts (361). Overexpression of icIL-1α in normal skin fibro-
blasts also induces expression of icIL-1ra (361). When icIL-1ra is 
overexpressed in cultures in normal human skin fibroblasts via 
transfection with a viral vector (pLXSNicIL-1ra type 1), it induces 
a myofibroblast phenotype characterized by increased expression 
of αSMA and PAI-1 (362).
Treatment of SSc lesional fibroblasts with IL-1α siRNA resulted 
in decreased proliferation and production of IL-6 and CI, whereas 
stably transfecting with icIL-1α induced proliferation and IL-6 
and CI synthesis (363).
TGF-β Receptor-Smad Signaling in Fibroblasts
A great deal of effort has elucidated the complex receptor engage-
ment and signaling of TGF-β and its 1, 2, and 3 isotypes that 
occur in mammals and which have been the topic of several 
recent reviews (364–367). TGF-β1, 2, and 3 are synthesized as 
inactive propeptides which have to be cleaved intracellularly by 
the protease, farin, to generate active 25 kDa MW, active TGF-
β1, 2, or 3. The active TGF-β is bound by the cleaved amino 
terminal peptide called “latency-associated peptide” (LAP) and, 
in connective tissue, the latent TGF-β1-LAP complex is bound 
to latent TGF-β1-binding protein (LTBP), which is termed 
“large latent complex” (LLC) (365, 368). Latent TGF-β can be 
activated by interaction with integrins and by several proteases 
such as thrombin, plasma transglutaminase, cathepsin D, and 
plasmin (369). There are three classes of TGF-β receptors. TGF-β 
receptor 1 has two forms: ALK1 (found mainly in endothelial 
cells) and ALK5 (which is present in most cells) (367). TGF-β 
receptor 2 forms a heteromeric complex with type 1 recep-
tors and phosphorylates it, setting in motion IC signaling via 
receptor-regulated Smads (R-Smads) which are type 1 receptor 
specific [i.e., ALK1 causes Smad1/5/8 phosphorylation while the 
predominant ALK5 causes Smad2/3 phosphorylation (367)]. The 
phosphorylated R-Smads complex with Smad4 and in the nucleus 
interact with co-activators [e.g., CREB-binding protein (CBP)/
p300] and co-expressors (e.g., Ski/Sno) to transcriptionally 
activate or repress target genes (367). Inhibitory Smads (Smad 
6 and 7) can bind to TGF-β type 1 receptors and to Smad4 or 
effect ubiquitination and proteasomal degradation (367). A 
coreceptor called endoglin, of which there are two spliced variants 
called short and long forms, can (under different conditions by 
interacting with ALK1 or ALK5) decrease or enhance TGF-β 
signaling, respectively (367). Betaglyan (“type 3” TGF-β recep-
tor) can also act as a coreceptor by facilitating TGF-β binding/
interaction with type 1 and 2 TG-β receptors (370). CTGF can 
also interact with TGF-β type 1 and 2 receptors and facilitate 
Smad3 signaling, which has a pro-fibrotic effect (367). Other 
members of the TGF-β superfamily including Activin (A, B, and 
AB), bone morphogenic proteins (BMPs), and growth differentia-
tion factors utilize components of the TGF-β receptor complex 
(366). In addition to the canonical Smad-dependent pathway 
described above, TGF-β can signal through non-canonical Smad-
independent Wnt, MAPK, phosphatidylinositol-3-kinase/AKT, 
and Rho-like GTPase pathways (366). Activating transcription 
factor 3 (ATF3), which regulates oxidation and cellular stress, 
is upregulated in SSc dermal fibroblasts by TGF-β; and ATF3 
suppresses TGFG-β-induced proliferative effects via interaction 
with Smad3 in a c-Jun-dependent manner (371).
Recently, it was reported that the fibrogenic effect of IL-6 in 
fibroblasts is brought about by binding of IL-6 to soluble IL-6 
receptor (IL-6R) by a JAK1 and STAT3-dependent mechanism 
that is mediated through Gremlin-1, which utilizes TGF-β type 1 
and 2 receptors and the TGF-β signaling pathway dependent on 
Smad3 that leads to CI gene expression, but is not dependent on 
TGF-β protein (372).
Transforming growth factor-β induces the early response gene 
(Egr-1), via a Smad-independent pathway via MEK1/2/ERK signal-
ing (373). Overexpression of Egr-1 induces CI gene upregulation 
(374). In addition, IL-13 and insulin-like growth factor-binding 
protein-5 (IGF-BP-5) have been shown to induce Egr-1 expression 
by MAPK signaling pathway (375). Other extracellular signals 
which are relevant to SSc [such as PDGF, hypoxia, HGF, or LPS 
(bacterial LPS), oxidative stress, thrombin, LPA, ultraviolet light, 
cigarette smoke, mechanical strength, ischemia-reperfusion, 
and T-cell receptor ligature] have been shown to increase Egr-1 
expression (373). TGF-β also induces Egr-3 by canonical Smad3 
signaling, and Erg-3 overexpression stimulates CI gene expression 
(376).
Antifibrotic Mediators
Bone morphogenic protein-7, although a member of the TGF-β 
superfamily, stimulates fibroblast chemotaxis like TGF-β1, but 
does not induce CI, fibronectin, hyaluronan, or TIMP synthesis 
(377). BMP-7 also inhibits fibrogenic properties of TGF-β1 (378) 
and signals through a receptor complex structurally different 
from that of TGF-β and utilizes SMAD1/5/8 (365). IL-10 inhibits 
both proliferation and CI synthesis by fibroblasts (379). Certain 
IL-10 genotypes have been associated with development of SSc in 
Caucasian and Japanese subjects (380). TNFα inhibits CI, stimu-
lates MMP-1 synthesis by fibroblasts, and is a potent chemoattract-
ant for these cells (381). IFNγ is a potent inhibitor of expression 
of CI and CIII mRNA and protein by cultured SSc fibroblasts 
in vitro (382). To what extent BMP-7, TNFα, IL-10, IFNγ, or other 
antifibrotic mediators or mechanisms try to counter the drivers of 
fibrosis such as TGF-β, IL-4/IL-13, IL-6/IL-6R-Gremlin-1 in SSc is 
unknown but provides candidates to be the focus of future studies.
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Effect of blocking TNFα with etanercept was assessed in the BLM 
scleroderma mouse model. Compared to vehicle-treated mice, the 
etanercept-treated mice had less dermal fibrosis and lower serum 
levels of TGF-β1 than controls not treated with etanercept (383). 
Etanercept has not been efficacious in ameliorating dermal fibrosis 
in patients with SSc (384) (see Table 3).
Peroxisome proliferation-activated receptor gamma-γ, when 
engaged by ligands of different types, blocks TGF-β-mediated 
fibrotic responses in vitro in cultured fibroblasts and in various 
fibrotic animal models in vivo (81, 82). PPARG rs310746 is associ-
ated with SSc (83).
In the cGVHD murine model of scleroderma induced by 
transferring splenocytes from B10.D2 donor mice into BALB/c 
recipients, tolerizing the recipient BALB/c mice by oral administra-
tion of protein extract of BALB/c spleens for 11 days after transfer of 
B10.D2 splenocytes was associated by upregulation of IL-10 and 
downregulation of IFNγ production by T cells from the BALB/c 
recipients and protected the recipient BALB/c mice from dermal 
fibrosis and other manifestations of cGVHD (385). IL-10 was likely 
produced by Tregs induced by oral tolerance induction by the 
BALB/c spleen extract and was likely responsible for suppression 
development of fibrosis (379).
Genome-wide Gene expression of Skin
The fibrogenic role of TGF-β, IL-13/IL-4, and Egr-1 in patients with 
SSc has been assessed by performing genome-wide gene expression 
studies on lesional and non-lesional skin biopsies from patients 
with dcSSc, lcSSc, morphea, and healthy controls. These studies 
show four intrinsic subsets of gene expression termed “diffuse 
proliferation” (further divided into diffuse1 and diffuse2) and 
containing only dcSSc patients; inflammatory group containing 
dcSSc, lcSSc, and morphea; limited group containing lcSSc; and 
a normal-like group containing normal, dcSSc, and lcSSc patients 
(386). Further comparisons were made subjecting TGF-β, IL-13/
IL-4, and Egr-1-stimulated normal dermal fibroblasts in culture to 
gene expression microarray analysis and comparing these fibroblast 
microarrays to gene expression arrays of biopsies of skin from SSc, 
morphea, and normal donors. TGF-β responsive gene signature 
was found in 10 out of 17 patients with dcSSc (59%) and none of 7 
lcSSc, none of 3 morphea, and none of 6 healthy controls (387). The 
dcSSc patients with the TGF-β-responsive signature had higher 
MRSS and likelihood of having ILD (387). The TGF-β signature-
positive dcSSc patients also were in the diffuse-proliferation 
subset; however, one in the diffuse-proliferation subset did not 
have the TGF-β signature. This suggests that only a subset (and 
not all) SSc patients have the TGF-β signature. The fibroblast Egr-
1-responsive gene signature was present in the skin biopsies from 
diffuse-proliferation subset of dcSSc patients, but was not present 
in biopsies of patients with lcSSc, morphea, or healthy controls 
(388). The IL-4 response signature overlapped approximately 60% 
with the IL-13 response signature, which were both enriched in the 
SSc inflammatory subset (389). Expression in skin biopsies from 
SSc patients of the IL-13 pathway activation [as well as transcripts 
of IL-13 receptor components (IL-13RA1 and IL-4RA)] correlated 
with MRSS (389). Expression of CCL2 (MCP-1) transcripts also 
correlated with MRSS and IL-13RA1 (389). This study also 
assessed gene expression profiling in skin of a sclerodermatous 
graft-versus-host disease (scl GVHD) model in Rag2–/– mice, 
which were found to also exhibit the IL-13 pathway activation 
resembling that in SSc patients of inflammatory subset (389). This 
observation is interesting, given that it has been hypothesized that 
fetal–maternal or maternal–fetal microchimerism might induce a 
cGVHD state in some patients with SSc as described above. Since 
IL-6 and IL-6R induces Gremlin-1 protein (which then signals 
through the canonical Smad-dependent pathway), it raises the 
question as to whether some of the TGF-β signature in the dcSSc 
diffuse-proliferation subset (discussed above) is actually due to 
Gremlin-1. Further studies would need to be done comparing 
Gremlin-1-induced gene signature in dermal fibroblasts with that 
of TGF-β1 to sort this out.
A more extensive genome-wide expression profiling skin 
biopsies involving analysis of additional pathway-specific gene 
signature for PDGF, S1P, PPAR-γ, TNFα, IFNα, NFκB, IL-13, 
IL-4, poly (I-C), and inomycin-phorbol 12-myristate 13-acetate 
(inomycin-PMA) was recently conducted by this group (390). 
Results showed IFNα signaling was strongly associated with 
early disease, compatible with the notion that innate immune 
response may be a feature in early disease which was contrasted 
with TGF-β signaling being a feature of later disease with worse 
MRSS (390). Surprisingly, PDGF signaling was most strongly 
associated with the fibroproliferative subset (more so than TGF-β), 
and the inflammatory subset exhibited strong activation of innate 
immune pathways including enrichment of IL-4, S1P, NFκB, LPS, 
poly(I-C), and TGF-β gene signatures (390). The findings support 
an earlier hypothesis by Gabrielli et al. that a stepwise process of 
SSc development begins with inflammatory (e.g., IFNα signaling) 
and continues with fibrosis (e.g., PDGF and TGF-β signaling) and 
ends in atrophy (391). IL-4 pathway was significantly enriched 
in the inflammatory subset more than IL-13, and suggests a TH2 
enhancement of immune response in patients within the inflam-
matory subset (390).
Most patients with dcSSc have some resolution with the pas-
sage of time of dermal fibrosis after the onset of their disease. 
This has been observed in several different studies clinically as 
decreases in the MRSS. In a large, single SSc center in the UK, 
131 patients with dcSSc had MRSS measured repeatedly up to 
36 months after onset of their disease (392). Three patterns were 
discernable as follows: those with high baseline MRSS that did 
not improve over 36  months from baseline (38%); those with 
high baseline MRSS that improved over 36 months from baseline 
(21%); and those with low baseline MRSS that improved over 
36 months from baseline (35%). The reason for these three clinical 
trajectories of change in MRSS over time is not apparent, but could 
be a function of different genetic backgrounds, different triggers, 
or other environmental modifications that either ameliorate or 
contribute to perpetuation of the disease. The patients received 
different medications; however, clinical MRSS response or survival 
could not be attributed to any of the medications (392). The fact 
that most of these patients with dcSSc had improvement in their 
MRSS suggests that the myofibroblast phenotype responsible for 
excessive ECM deposition does not persist, that the fibrotic skin 
can revert toward normal, and that a normal-like homeostasis 
can be re-established in such patients. This study suggests that 
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those dcSSc patients with persistently high MRSS likely have a 
continuous presence of a driver of dermal fibrosis that constantly 
stimulates the fibroblasts to maintain the myofibroblasts phenotype 
with maintenance of increased ECM in their dermis. Application 
of the genome-wide gene expression studies of skin biopsies, in 
a cohort such as this one in which patients have skin biopsied 
repeatedly over several years, may shed light on the mechanisms 
responsible for the three different MRSS trajectories over time, 
and would answer the question whether the inflammatory subset 
morphs into the fibroproliferative subset.
vitamin D and Fibrosis
Vitamin D has a variety of antifibrotic actions. Studies in vitro 
have demonstrated 1,25(OH)2D3 inhibits growth of murine 
fibroblasts (393–397), inhibits fibroblast-mediated contraction 
of CI gels (largely a TGF-β-stimulated function) (398), inhibits 
fibroblast synthesis of IL-6 and IL-8 (399, 400), and inhibits 
production of plasminogen activator (401). It was also observed 
that 1,25(OH)2D3 in  vitro inhibited CI and CIII synthesis by 
fibroblasts grown from different human tissues including bone 
marrow, lung, and skin (402, 403). In mice, in vivo administration 
of 1,25(OH)2D3 has been shown to ameliorate renal interstitial 
fibrosis, glomerulosclerosis in rats, and reduce conversion of 
adipose tissue to fibrous tissue in mouse skin exposed to chronic 
UV irradiation (404, 405).
The cutaneous formation and metabolism of VitD in patients 
with SSc has been reported to be normal (406–408). In one 
report, fibroblasts grown from biopsies of lesional skin from 
patients with SSc and from healthy volunteers were inhib-
ited in proliferation and CI synthesis to a similar extent by 
1,25(OH)2D3 addition to the fibroblast culture (409). The VitD 
receptor (VDR) in SSc lesional skin fibroblasts is reported to 
be decreased, likely due to TGF-β’s ability to downregulate the 
VDR (410).
Studies using a mouse mesenchymal multipotent cell line 
revealed that 1,25(OH)2D3 promoted increased expression and 
nuclear translocation of the VDR; decreased expression of TGF-
β1 and plasminogen activator inhibitor (SERPINE 1); decreased 
expression of CI I, III, and other CI isoforms; and increased expres-
sion of several other antifibrotic factors including BMP-7, MMP-8, 
and follistatin [an inhibitor of the pro-fibrotic factor, myostatin 
(411)]. Studies in rat interstitial myofibroblasts showed that 
1,25(OH)2D3 inhibited in a dose-dependent manner (10–9–10–6 M) 
TGF-β1-induced de novo αSMA expression and suppressed CI 
and TSP-1 expression induced by TGF-β1, which was shown to 
be mediated by upregulated HGF (412).
Slominski et al. have discovered the skin and other tissues in 
humans synthesize other VitD derivatives [including 20(OH)D3, 
20,23(OH)2D3, and 17,20(OH)2pD] that, also like 1,20(OH)2D3, 
in vitro inhibit CI and hyaluronan synthesis by fibroblasts grown 
from normal or SSc lesion skin (144). Unlike VitD3, 25(OH)D3, 
or 1,25(OH)2D3, these novel endogenously produced VitD analogs 
are non-calcemic when given in high doses to mice. 20(OH)D3 
also suppressed development of dermal fibrosis in the BLM, 
scleroderma mouse model (413). These results suggest multiple 
endogenous forms of VitD3 have antifibrotic properties that may 
prove useful in SSc as therapeutic agents in the future.
Lysophospholipids and Fibrosis
Lysophosphatidic acid induces fibroblast chemotaxis and prolifera-
tion (414). LPA induces αvβ6 integrin-mediated TGF-β activation 
by engaging LPA2 receptors on epithelial cells and makes fibroblasts 
resistant to apoptosis, which is a characteristic of SSc lesional 
fibroblasts that would prolong their survival (415, 416). Evidence 
that LPA is involved in myofibroblast formation in SSc lesional 
skin was suggested by the finding that fibroblasts cultured from 
skin of SSc patients exhibited increased LPA-activated chloride 
current, which is a hallmark of LPA-induced myofibroblasts (417). 
AMO95: a selective small molecule inhibitor of LPA1 signaling 
(AMO95) protected mice from developing BLM-induced skin 
fibrosis and increased regression of established BLM-induced skin 
fibrosis (418). Contrary to the results in the BLM skin fibrosis 
model in which LPA2 knockout did not affect dermal fibrosis, in the 
BLM lung fibrosis model, LPA2 knockout mice exhibited reduced 
lung injury, fibrosis, and fibronectin deposition in BLM-treated 
lungs (419). S1P facilitates migration of fibroblasts in response to 
a chemotactic gradient of fibronectin in a S1P2 receptor-dependent 
manner (420). S1P signals through the Smad pathway utilized by 
TGF-β1 in fibroblasts and other cell types and mimics TGF-β1 
pro-fibrotic effects in that it decreases MMP-1 and increases TIMP 
and CI production by fibroblasts (421–423). SSc dermal fibroblasts 
express more S1P3 receptors than control donor fibroblasts and 
exhibit an exaggerated pro-fibrotic response to TGF-β1 (421). 
Furthermore, S1P levels are elevated in sera of patients with SSc 
(214). As mentioned above, S1P gene signature is prominent in 
the inflammatory subset (390). Fingolimod (FTY720) has both 
agonist and antagonist effects in different S1P receptors and 
modulates lymphocyte trafficking, monocyte/macrophage biology, 
dendritic cell biology, and enhances Treg function at marginal zone 
B lymphocytes (144). When administered to chronic scleroderma 
graft-versus-host disease (cScl-GVHD) mice, FTY720 in either 
preventative or therapeutic protocols reduced fibrosis, expanded 
splenic myeloid suppressor cells, increased Tregs and B regulatory 
cells (Bregs), protected against vascular damage, reduced serum 
S1P and E-selectin levels, reduced numbers of inflammatory cells 
in skin, and reduced dermal expression of mRNA for TGF-β1, 
MCP-1, MIP-1α, RANTES, TNFα, IFNγ, IL-6, IL-10, and IL-17A 
(424). FTY720 also returned phosphatase and tensin homolog 
(PTEN) and Smad3 phosphorylation to normal levels in cScl-
GVHD mice (424). Although FTY720 is approved to treat MS, 
its use in SSc clinical trials has not been reported.
The endocannabinoid System and SSc
The ECS is an endogenous regulatory network made up of multiple 
GPCRs and a series of endogenous arachidonic acid derivatives, 
which act in an autocrine fashion and seem to play a homeostatic 
role affecting diverse key biologic and physiologic processes 
including angiogenesis, cell proliferation, apoptosis, differentia-
tion, metabolism, immune function, and vascular tone that may 
have implications for SSc pathogenesis and potential therapeutic 
targets. The term “endocannabinoid” generally refers to the first 
two characterized endocannabinoids (ECs), anandamide (AEA) 
and 2-arachidonoyl glycerol (2-AG), though a number of endog-
enous cannabinoid receptor agonists have since been discovered. 
June 2015 | Volume 6 | Article 27226
Pattanaik et al. Pathogenesis of SSc
Frontiers in Immunology | www.frontiersin.org
AEA and 2-AG may be degraded into free arachidonic acid by 
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 
(MAGL), respectively, but may also be metabolized by lipoxyge-
nases, cyclooxygenase 2 (COX-2), and P450 epoxygenases, and 
acyl transferases yielding a vast library of EC analogs with differ-
ent actions and target receptors (425). Some of these metabolites 
engage EC receptors, while others have been demonstrated to 
modulate the activity of ECs via “entourage effects” at cannabinoid 
receptors 1 (CB1) and 2 (CB2), inhibition or potentiation of ECS 
degradation, activation of downstream targets such as PPARγ or 
metabolic interconversion (426).
Efforts to identify new cannabinoid receptors are ongoing; but 
CB1, CB2, and GPR55 are among the most extensively studied, and 
recent studies clearly demonstrate that all three of these receptors 
are activated by AEA and play a key role in transduction of EC 
signaling. Interestingly, CB1, CB2, and GPR55 have also been 
shown to modulate one another’s activity via heteromerization, 
cross-antagonism, and other strategies (427, 428). GPR18 (also 
known as “abnormal cannabinoid receptor”), another candidate 
cannabinoid receptor, may play a role in EC-mediated central 
blood pressure control and peripheral vascular tone (429, 430). 
Unlike CB1, CB2, and GPR55; however, activation of this recep-
tor requires FAAH-mediated metabolism of AEA or 2-AG to 
N-arachidonoyl-glycine (431). It is interesting to speculate that if 
there is reduced FAAH in tissue-expressing GPR18 in patients with 
SSc as has been found in SSc dermis, then this might contribute 
to vasoconstriction and hypertension (432). Substantial cross talk 
has also been established between the ECS and a network of non-
selective action channels known as the transient receptor potential 
vanilloid (TRPV) family, which serve to integrate mechanical 
and environmental stimuli with local autocrine signals to effect a 
variety of cell processes (433, 434).
endocannabinoid System as a Therapeutic 
Target in SSc
The ECS is an appealing potential target for treatment of SSc, as 
it modulates endothelial cell function, vascular tone (including 
pulmonary artery vasodilation), the innate immune response to 
injury, autoimmunity, and fibrogenesis (435–440).
Endocannabinoid Modulation of the Immune System
The general effect of cannabinoids on cells of the immune system 
is to act as immunosuppressive and anti-inflammatory agents. 
Although immune cells express more CB2 than CB1, both recep-
tors and other non-CB receptors (such as PPARγ and GPR55) 
have been implicated in effecting immunomodulatory actions 
of cannabinoids (441, 442). CB1 mRNA and protein expression 
in/on immune cells is responsive to cellular activation signals, 
i.e., cell type, cannabinoid ligand type, and immune stimulus-
dependent (443). Of relevance to SSc, IL-4 is specifically able via 
STAT5 pathway to induce CB1 mRNA in human T cells (444). 
Dendritic cells exposed to cannabinoids undergo NFκB-dependent 
apoptosis and reduce production of IL-12, which is important in 
priming Th0 cells to a Th1 orientation (445, 446). Cannabinoids 
induce apoptosis of T cells via CB1 and CB2 engagement and 
effect a Th2 polarization (e.g., increased IL-4 by T cells) while 
decreasing Th1 polarization (e.g., decreased IL-12 by DC) but 
also suppress activation, differentiation, and expansion of T cells 
(443, 447, 448). B cells are affected by cannabinoids in several 
ways, including direct effects on activation, differentiation, and 
proliferation but also via effects on T cells that provide help to 
B cells (449). The effect of cannabinoids on B cells to suppress 
IgM and enhance IgE production apparently is mostly via engage-
ment of CB2 (450). Production of pro-inflammatory cytokines 
(including TNFα, IFNγ, IL-2, and IL-1β) is suppressed in vitro and 
in vivo, by engaging CB2 by cannabinoids or other CB2 agonists 
(451–453). Of particular relevance to SSc is that mast cell activation 
is inhibited by 2-AG (454). The CB2 agonist, Gp1a, was found to 
suppress clinical disease in the EAE mouse model with a reduction 
in Th1 and Th17 cells in peripheral lymphoid organs. Analysis 
of the CD4+ cells in vivo in the periphery revealed Gp1a-treated 
mice had lower levels of expression of T but also RORγt (Th17 
marker) and exhibited increased Foxp3 and GATA-3 expression 
(455). Under polarizing conditions in  vitro, Gp1a suppressed 
Th1 and Th17 development of CD4+ T cells (455). The role of 
the ECS in innate and adaptive immune dysregulation in SSc is 
an area for further investigation, and these results with this CD2 
agonist suggest similar agents might decrease autoimmunity and 
autoantibody production in SSc.
Endocannabinoid Modulation of the Vasculature
The upregulation of ICAM-1 and VCAM-1 on the endothelium 
of human coronary arteries by treatment with TNFα or LPS is 
inhibited by the CB2 agonist drug, JWH-133 (437). Engaging CB2 
in rat coronary arteries by AEA induced the coronary arteries to 
dilate (456). Blocking CB1 on isolated human coronary smooth 
muscle cells by the CB1 antagonist, rimonabant, reduced ability 
of the smooth muscle cells to migrate and proliferate in response 
to PDGF (438). The ECs (AEA and virodhamine) were found to 
have a potent vasodilatory effect on preconstricted isolated human 
pulmonary artery rings that was endothelium-dependent and 
likely involved PGE2 (436). The effect of AEA and virodhamine 
was CB1- and CB2-independent but involved a third receptor 
termed “endothelial cannabinoid receptor” (436). These studies 
suggest that a target for development of treatment for PAH in SSc 
might be based on virodhamine-like drugs that are agonist for the 
endothelial cannabinoid receptor.
Endocannabinoid Modulation of Fibrosis
C57BL/6 mice with either TRPV1 receptor or calcitonin G-related 
peptide (CGRP) knocked out compared to WT mice developed 
enhanced dermal fibrosis after repeated subcutaneous injection 
of BLM (434). This suggests that TRPV1 receptor and CGRP have 
antifibrotic effects and may have relevance to patients with RP 
and SSc since skin biopsies from patients with SSc have reduced 
numbers of CGRP-immunoreactive C fibers and would likely 
have reduced vasodilatation from CGRP in response to stressors 
that trigger RP (434). It is unclear whether other TRPV1 receptor 
engagement or CGRP effects are operative to protect against fibro-
sis. TRPV4 has been implicated as a mechanosensor in endothelial 
cells and fibroblasts, and has been shown to stimulate myofibro-
blast differentiation in rat cardiac fibroblasts via integration of 
mechanical and soluble (autocrine) signals, and pretreatment with 
the TRPV4 antagonist, AB159908, resulted in significant inhibition 
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of TGF-β1-induced myofibroblasts differentiation of cardiac 
fibroblasts (457). 5,6-EET (generated by activation of PAR-2 by 
mast cell tryptase or Factor Xa) has been implicated as the most 
likely autocrine mediator contributing to activation of TRPV4, 
though other autocrine signals may be involved as well, with the 
known TRPV4 agonist N-acyl taurine being another possible 
candidate. It is worth noting that this system of channels seems to 
be dysregulated in dcSSc fibroblasts with profound downregulation 
of TRPV2 (and possibly TRPV1) and overexpression of TRPV4. 
While the role of TRPV1 and TRPV2 is less clear, TRPV4 is known 
to stimulate myofibroblast differentiation in response to activation 
by mechanical stress and arachidonic acid derivatives. In normal 
wound repair, release of the myofibroblast from this mechanical 
stress signal plays a role in inducing apoptosis or, alternatively, may 
help drive the myofibroblast back into a quiescent fibroblast. Given 
that TRPV4 remains overexpressed in the dcSSc fibroblast, this 
may suggest that certain autocrine signals are present, which alter 
the cellular milieu in favor of constitutive activation of TRPV4, 
thus rendering the myofibroblast incapable of responding appro-
priately to mechanostress signaling. AEA and 2-AG activation of 
TRPV4 is indirect and requires hydrolysis of these compounds 
to free arachidonic acid, which is then converted into the potent 
TRPV4 agonist 5,6-EET. The fatty acid amide N-acyl-taurine was 
recently discovered to be a potent agonist of TRPV4, as well, and 
is likely overexpressed in SSc owing to underexpression of FAAH 
(432). This compound was shown to be elevated 10-fold following 
experimental inactivation of FAAH, with highest levels noted in 
the lungs and kidneys (458). Furthermore, inaction of FAAH 
in mice increases dermal fibrosis in response to subcutaneous 
administration of BLM (432).
Serine proteases activate PARs, which have been associated 
with fibrosis of internal organs (459–461). PAR-1 is expressed by 
keratinocytes, endothelial cells, and fibroblasts, while PAR-2 is 
expressed in suprabasal keratinocytes in SSc lesional skin and in 
healthy donor skin (462). There is more expression of PAR-1 by 
fibroblasts in biopsies of SSc lesional skin than by fibroblasts in 
biopsies of normal donor skin, and PAR-2 was expressed only by 
SSc lesional skin fibroblasts and not by normal donor fibroblasts 
(462). A large portion of fibroblasts in samples from SSc lesional 
skin were myofibroblasts, staining positive for αSMA suggesting 
that PAR-1 and PAR-2 may be involved in fibrosis development 
in SSc (462). PAR-1 is increased on SSc-associated ILD myofibro-
blasts, and when it is inhibited by the direct thrombin inhibitor, 
dabigatran, there is abrogation of formation of myofibroblasts, 
αSMA, and production of CI (463). Agonists of PAR-2 include mast 
cell tryptase and Factor Xa, and mast cells have been demonstrated 
to stimulate human lung fibroblast proliferation via activation of 
PAR-2.
It is worth noting the importance of COX-2 in the metabo-
lism of ECs – specifically regarding 2-AG, which is more readily 
metabolized by COX-2 than AEA and has also been shown to 
activate PPARγ via a mechanism that is COX-2 dependent. Recent 
studies suggest the COX-2 metabolite of 2-AG, 15-deoxy-PGJ2-G, 
activates PPARγ (464) and that inhibition of IL-2 secretion by 
AEA in murine splenocytes is attenuated by COX-2 inhibition 
and also partially antagonized by PPARγ inhibition (465). Further 
work should be directed at evaluating PPARγ as a downstream 
target of the oxygenated metabolites of AEA and 2-AG, as this 
nuclear receptor is known to modulate fibrogenesis (likely by being 
a transcriptional repressor of TGF-β), autoimmunity, and a wide 
range of other physiologic processes (82, 466). 2-AG is oxygenated 
by COX-2 and other PG synthases to produce several different 
glycerol-esters of the prostaglandins (PG-Gs). During the early 
stages of inflammation, in which microsomal prostaglandin E2 
synthase (mPGES)-1 is high, one would expect to see higher levels 
of PGE2-G. Similarly, during resolution, in which PGD2 and its 
spontaneous degradation products predominate, one would expect 
to see higher levels of PGD2-G and its metabolites. Interestingly, 
the EC analog of 2-AG, which is known as 15-deoxy-PGJ2-G, also 
has been shown to activate PPARγ and this cyclopentanone-EC 
derivative may be the mediator of 2-AG’s activation of PPARγ. 
Further characterization of the P450-derived epoxides of AEA 
and 2-AG is needed, especially given the importance of P450, 
epoxygenase in PAR-2-mediated sustained activation of TRPV4, 
which may play a role in perpetuating fibroblast activation.
The efficacy of several cannabinoid agonists in attenuation of 
fibrosis has been demonstrated in both the BLM and hypochlo-
rite murine models of SSc. Additionally, these compounds have 
been shown to counter several behavioral abnormalities of SSc 
fibroblasts, including reversal of myofibroblast differentiation and 
decreased resistance of SSc myofibroblasts to apoptosis, with the 
ultimate effect of decreased ECM deposition and attenuation of 
fibrogenesis. The exact mechanism by which these cannabinoid 
agonists exert their antifibrotic action is still a matter of debate, 
but it seems to be mediated in part by activation of CB2 and 
PPARγ. CB1 and CB2 are both overexpressed in dcSSc fibro-
blasts. Twenty-four hour incubation with the CB1/CB2 agonist, 
WIN55,212-2, resulted in agonist-induced inhibition of both CB 
receptors, which was reversible after agonist withdrawal (439). 
After 10 μM WIN55,212-2 incubation, a reduction in CI mRNA 
and protein was observed in both dcSSc and healthy fibroblasts 
(439). TGF-β and CTGF mRNA expression, as well as IL-6 levels 
were also substantially decreased after exposure to WIN55,212-2 
(439). Analysis for αSMA by Western blotting, RT-PCR, and 
immunocytochemistry showed that WIN55,212-2 induced 
reduction in αSMA expression by 43% and increased by twofold 
the number of apoptotic fibroblasts from patients with dcSSc but 
not in fibroblasts from healthy donors (439). Pre-incubation of 
dcSSc and healthy fibroblasts with synthetic cannabinoid receptor 
antagonists AM281 (CB1 antagonist) and AM630 (CB2 antagonist) 
did not significantly reverse the effects of WIN55,212-2 on CI neo-
synthesis, inhibition of IL-6, or fibroblast apoptosis, indicating that 
the antifibrotic actions of WIN55,212-2 are mediated, in part, by 
pathways not involving CB1 and CB2, perhaps as the authors sug-
gest by transducing pathways involving p-ERK (439). Incubation 
of dcSSc fibroblasts and healthy controls with WIN55,212-2 was 
noted to result in decreased phospho-ERK-1/2 protein expres-
sion in both groups (439). WIN55,212-2 was found to prevent 
BLM-induced dermal fibrosis in DBA/2J mice in vivo. Levels of 
phospho-Smad2/3 were analyzed and found to be significantly 
lower after WIN55,212-2 exposure. Subcutaneous inflammatory 
cell infiltration, dermal thickness, and CI content were compa-
rable to the control group (440). BALB/c mice injected daily for 
6 weeks with PBS or hypochlorite were injected intraperitoneally 
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with PBS or with WIN55,212-2, an agonist of CB1 and CB2, or 
with JWH-133, a selective agonist of CB2. Both WIN55,212-2 and 
JWH-133 prevented development of skin and lung fibrosis, as well 
as fibroblast proliferation and formation of autoantibodies (467).
As mentioned above, FAAH levels are markedly reduced 
in biopsies of SSc lesional skin compared to skin from healthy 
donors, and mRNA for FAAH expression in cultured lesional 
skin fibroblasts from patients with SSc was also reduced from that 
expressed by cultured normal donor dermal fibroblasts (432). The 
induction of BLM skin fibrosis in FAAH null mice or in normal 
mice treated with the FAAH inhibitor, JNJ1661010, resulted in a 
marked increase in skin fibrosis at the BLM injection site (432). 
Furthermore, blocking CB1 receptor in BLM-treated mice with 
FAAH blocked by JNJ1661010 resulted in a marked increase in 
skin fibrosis at the BLM injection site (432). Additionally, block-
ing CB1 receptor in BLM-treated mice with FAAH blocked by 
JNJ1661010 prevented the enhanced fibrosis induced by BLM 
treatment, whereas blocking CB2 further enhanced skin fibrosis in 
BLM-treated mice with FAAH blocked by JNJ1661010, suggesting 
CB1 mediated fibrosis whereas CB2 dampened fibrosis as a result 
of increased EC present because of blocking FAAH (432).
The role of the CB1 receptors in the BLM skin fibrosis model 
and Tsk-1/+ mice model was assessed using CB1KO mice (468). 
WT and CB1KO mice were treated with BLM and with the CB1 
selective agonist N(a-chloroethyl)-5Z, 8Z, 11Z, 14Z eicosatetraena-
mide (ACEA) (468). CB1KO mice were protected from developing 
BLM dermal fibrosis; however, crossing CB1KO mice with Tsk-1/+ 
mice did not prevent fibrosis (468). This suggested that fibrosis 
associated with inflammation was dependent on CB1 expression 
or leukocytes. Indeed, chimeric bone marrow studies revealed 
that CB1 on leukocytes was essential for leukocyte infiltration 
and fibrosis in the BLM skin fibrosis model induced by the CB1 
agonist (468).
These preclinical studies of CB receptor agonists/antagonist 
provide useful information for translation of these or similar CB 
receptor active agents for treatment of SSc.
Conclusion
Systemic sclerosis is one of the most complex systemic auto-
immune diseases that target the vasculature and connective 
tissue-producing cells (namely fibroblasts/myofibroblasts) and 
components of the innate and adaptive immune systems – all three 
of which themselves interact and affect each other. The disease 
is heterogeneous in its clinical presentation that likely reflects 
different genetic background or triggering factor influences on 
the vasculature, connective tissue cells, and immune system. 
The roles played by other ubiquitous molecular entities (such as 
lysophospholipids, ECs, and their diverse receptors) in influencing 
the vasculature, immune system, and connective tissue cells are just 
beginning to be realized and studied and may offer new therapeutic 
approaches to treat SSc.
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